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ABSTRACT OF THE DISSERTATION 
 
Role of mTORC1 and Autophagy in the Regulation of 
Fludarabine-resistance in Leukemic B-cells 
 
By Arishya Sharma 
 
Deregulated mTORC1 contributes to tumorigenesis and chemoresistance. 
However, mTORC1-specific inhibitors (rapalogs) show modest efficacy in the 
clinic, as they unleash the feedback inhibition on upstream, prosurvival 
pathways. An alternative approach is to target downstream functions of 
mTORC1. We investigated acquired resistance to fludarabine (Flu), a purine 
analog, active agent for chronic lymphocytic leukemia (CLL). Elevated phospho-
p70S6k (T389), an mTORC1 activation marker, predicted Flu resistance in a 
panel of B-cell tumor lines, and primary CLL cells. However, the rapalogs 
induced moderate cell death in Flu-resistant (FluR) and primary CLL cells.   
Activation of oncogenic pathways, including mTORC1, induces profound 
metabolic reprogramming to provide energy and biosynthetic substrates for 
xi 
 
tumor growth. Therefore, we investigated the metabolic consequences of 
mTORC1 activation in FluR compared to Flu-sensitive (FluS) cells, aiming to 
identify selective vulnerability of FluR cells to interference with specific metabolic 
pathways (Aim1). Seahorse metabolic analysis revealed mTORC1-mediated 
increase in glycolysis and mitochondrial respiration, which was uncoupled from 
ATP synthesis in the FluR cells. Additionally, we observed increased mTORC1-
p70S6k dependent phospho-CAD (S1859) and, S-phase population in FluR cells, 
suggesting accelerated de novo pyrimidine biosynthesis. Consistently, siRNA-
mediated knockdown of p70S6K, and the pharmacological inhibition of the 
enzymes of de novo pyrimidine biosynthesis pathway, or associated 
mitochondrial respiration were selectively cytotoxic to FluR, but not FluS cells.  
Such oncogene-mediated metabolic reprogramming confers selective 
growth and survival advantage to cancer cells.  However, the by-products of 
unrestrained biosynthesis and exhaustive mitochondrial metabolism will cause 
metabolic stress. Autophagy, by removal and recycling of damaged cellular 
contents, functions as a prominent cellular metabolic stress adaptation pathway. 
This suggested autophagy might be critical in FluR cell survival. Given the dual 
role of autophagy, pro-death or –survival, we investigated the context-dependent 
role of autophagy in FluS and FluR backgrounds (Aim2). Consistent with the 
prosurvival role of autophagy under metabolic stress, FluR were addicted to 
AMPK-dependent, and BECN1-independent autophagy. In FluS cells, Flu-
induced cell death associated, BECN1-dependent autophagy. Therefore, we 
propose (i) upstream stimuli, such as overstimulation by chemotherapy treatment 
xii 
 
versus stimulation by metabolic stress within cellular threshold limits, and (ii) 
molecular regulatory inputs, BECN1-dependent versus AMPK-dependent, could 
be determining factors for pro-death versus pro-survival function of autophagy. 
Overall, our data support the hypothesis that targeting downstream 
functions of mTORC1, including pyrimidine biosynthesis, glucose metabolism, 
and autophagy in cells with deregulated mTORC1 could be an important and 
effective means to bypass rapalog resistance. We establish that mTORC1, 
metabolic reprogramming and, autophagy, are critical determinants of Flu-
resistance. Future studies delineating the mechanistic links between these three 
pathways are expected to yield fruitful insights into the understanding of 
chemoresistance in cancer. 
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CHAPTER I 
INTRODUCTION 
1.1 Overview of mTOR pathway  
Rapamycin (or sirolimus, the prototypical inhibitor of molecular target of 
rapamycin (mTOR) was serendipitously discovered as an antifungal agent in the 
soil of Rapa Nui in 1975 (1).  Since then, the mTOR inhibitors have continued to 
attract researchers as well as clinicians. Almost 40 years of magnificent 
research, including the recent mTOR omics—ribosome profiling, transcriptomics, 
metabolomics, and phosphoproteomics, has revealed that mTOR is the central 
growth and proliferation regulatory kinase (1). It integrates the inputs from major 
upstream growth and survival regulating stimuli, including— growth factors, 
energy, oxygen, amino acids, and cellular stress such as DNA damage to the key 
downstream pathways needed to sustain and grow, including—protein 
biosynthesis, nucleotide biosynthesis, lipid metabolism, glucose metabolism, 
autophagy, apoptosis, and cell cycle (2, 3). Clearly, to understand cell growth 
and survival, elucidation of function and regulation of mTOR is a key. 
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Conversely, deregulated mTOR signaling is frequently associated with 
development and drug resistance in cancer, metabolic, neurological, and genetic 
disorders (4). Yet, disappointingly the pharmacological inhibition of mTOR by 
rapamycin, especially in cancer treatment has shown modest efficacy in clinic, 
except for patients with renal cell carcinoma-,  tuberous sclerosis complex -, and 
lymphangioleiomyomatosis -related tumors (1). This critical question has been 
widely studied, and activation of pro-survival feedback loops and compensatory 
pathways in response to mTORC1 inhibition have been implicated in the 
phenomena (1).  
Current research in the field focuses on development and investigation of 
such dual inhibitors in the market that co-target both mTORC1 and these 
interfering pathways, especially PI3K, and various combination treatments are 
being investigated (1, 5). While such strategies are expected to improve the 
clinical efficacy, given the overwhelming networking of mTORC1, efforts are 
needed to develop better strategies to effectively exploit this pathway in the 
clinic. In this regard, investigation of the most “vulnerable" signaling pathway(s) in 
a given disease setting, not necessarily upstream or parallel, but also 
downstream of mTORC1 should be addressed. The future expects to see in the 
clinic mTORC1 inhibitors effectively combined with inhibitors of such “vulnerable” 
pathways. And, in addition, monotherapies targeting such “vulnerable” pathways 
in mTORC1-dependent disease conditions, where markers of mTORC1 pathway 
may be used as biomarkers to identify patients who will benefit the most. 
1.1.1 Domain structure of mTOR kinase  
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Mammalian target of rapamycin (mTOR) is a Ser/Thr kinase of the 
phosphatidylinositol 3-kinase-related kinases (PIKK) family (6, 7). The tertiary 
structure of mTOR (Figure1.1a) comprises— N terminal HEAT 
( HEAT (Huntingtin, Elongation factor 3, A subunit of protein phosphatase 2A and 
TOR1) repeats,  which participate in protein-protein interactions; a FAT (FRAP-
ATM-TRAAP) domain; the FRB (FKBP12-rapamycin-binding) domain; the 
Ser/Thr kinase domain, homologous to the phosphatidylinositol 3-kinase (PI3K) 
lipid kinase domain; and a FATC (FAT C-Terminal) domain at the C terminus of 
the protein (8, 9). 
1.1.2 mTOR Complex1 and mTOR Complex2 
mTOR forms two distinct multi-protein complexes- mTOR complex 1 
(mTORC1),  and mTOR complex 2 (mTORC2), which differ in their sensitivity to 
rapamycin, subunits, upstream regulatory signals, and downstream functions 
(Figure 1.1b) (7, 10).  
mTORC1, which is the main focus of this study, has 5 subunits (Figure 
1.1b) — (1) mTOR, the catalytic subunit, (2) regulatory-associated protein of 
mTOR (Raptor), acts as a scaffold regulates complex assembly and substrate 
binding, (3) mammalian lethal with sec-13  mLST8, also GβL, with unknown 
function. (4) DEP domain containing mTOR interacting protein (DEPTOR), and 
(5) proline-rich Akt substrate 40kDa (PRAS40) both are negative regulators of 
mTORC1.  mTORC2 has 6 subunits (Figure 1.1b) —  mTOR, mLST8, and 
DEPTOR being the same as in mTORC1. In addition, it has a rapamycin-
insensitive companion of mTOR (rictor), protein observed with rictor 1 and 2 
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(protor 1/2), and mammalian stress-activated map kinase-interacting protein 1 
(mSin1) (4, 7). 
mTORC1 regulates metabolism, autophagy, cell growth and proliferation 
in response to upstream signals, including growth factors, energy, oxygen, stress 
and amino acid levels (Figure 1.1b). mTORC2 responds to growth factors. 
Downstream functions of mTORC2 include regulation of cytoskeletal organization 
and cell survival (Figure 1.1b) (1). 
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Figure 1.1 (a) The domain structure of mTOR. At the N- terminus of mTOR 
are:tandem HEAT repeats: anti-parallel α-helices important for protein–protein 
interaction; The FAT and FATC domains: modulate the activity of the kinase 
domain; The FRB domain: is the docking site of the FKBP12–rapamycin complex 
(9). (b) The two mTOR complexes, mTORC1 and mTORC2, their subunit 
composition, upstream inputs, downstream functions; and, rapamycin sensitivity 
are shown. mTORC1 coordinates cellular growth and proliferation in response to 
upstream stimuli, including stress, growth factors, oxygen, energy levels, and 
nutrients, via regulating metabolism and autophagy (described in detail in the 
text). mTORC2 regulates cell survival and cytoskeleton in response to in 
response to growth factors (adapted from (1)). 
, 
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1.1.3 Regulation of mTORC1  
mTORC1 activity is regulated by 5 major inputs—growth factors, energy, 
oxygen, stress and amino acids (Figure 1.3). In addition recently, activation of 
wnt, hippo and notch signaling pathways have been shown to regulate mTORC1 
(Figure 1.3) (2, 6).  
Most of the upstream inputs to mTORC1 signaling converge at the 
heterotrimeric tuberous sclerosis complex (TSC) protein complex, that comprises 
TSC1, TSC2 and Tre2–Bub2–Cdc16 (TBC) 1 domain family member 7 
(TBC1D7) (Figure 1.2). The TSC2 protein is a GTPase-activating protein (GAP) 
specific for Ras homolog enriched in brain (Rheb), which is a ubiquitously 
expressed small GTPase of the Ras superfamily, essential for mTORC1 
activation (Figure 1.2).  TSC1 and TBC1D7 are needed for TSC2 to be fully 
active and complex stability. Rheb, in its GTP-bound form (RhebGTP), activates 
mTORC1 by direct interaction with the mTOR kinase domain. In the absence of 
activating signalling, Rheb is maintained in its GDP-bound state (RhebGDP) by 
the TSC that blocks mTORC1 activation (Figure 1.2) (3, 11).   
1.1.3.1 Growth factors. The stimulation of tyrosine kinase receptors 
(RTKs) or G protein coupled receptors (GPCRs) by a variety of growth factors or 
cytokines leads to mTORC1 activation via downstream PI3K-AKT and Ras- 
Extracellular signal-regulated kinases (ERK) pathways (Figures. 1.2 and 1.3) (2, 
3, 12). Ligand binding activates RTKs, phosphotyrosine residues of RTKs or their 
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Figure 1.2 mTORC1 activation by Growth factors and insulin receptors. Growth 
factors suppress the TSC1/TSC2 complex function, a negative regulator of 
mTORC1, resulting in indirect activation of mTORC1. TSC2 acts as a GAP that 
converts active Rheb-GTP to inactive, Rheb-GDP form. Activation of RTKs 
activate AKT by PI3K/PDK and mTORC2 mediated phosphorylations. Active AKT 
inhibits the TSC1/2 complex by direct phosphorylation of TSC2, and 
phosphorylation of PRAS40, mTORC1 suppressor. Also, activation of RTKs 
activates MAPK pathway, ERK and RSK phosphorylate TSC2 and inhibit TSC1/2 
complex. (adapted from: (3)) 
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adaptor proteins then recruit PI3K to the plasma membrane  via Src Homology 2 
(SH2) domains of its regulatory subunit (p85) resulting in activation of the 
catalytic p110 subunit of PI3K which, in turn, generates phosphatidylinositol-
3,4,5- trisphosphate (PIP3) by phosphorylating phosphatidylinositol-4,5-
bisphosphate (PIP2). PIP3 then recruits AKT and phosphoinositide-dependent 
protein kinase (PDK1) to the plasma membrane via their pleckstrin homology 
(PH) domain resulting in phosphorylation at Thr308 and activation of AKT. Full 
AKT activation requires mTORC2-dependent phosphorylation at Ser473.  The 
active AKT phosphorylates TSC2 at specific target sites and inhibits TSC-
complex, leading to mTORC1 activation (Figure 1.3). Also, AKT phosphorylates 
proline-rich Akt/PKB substrate 40 kDa (PRAS40) at Thr246 resulting in 
dissociation of this inhibitor from mTORC1 (Figure 1.3) (3, 8). 
In addition, activation of RTK triggers Ras-GDP/Raf/MEK/ERK cascade. 
ERK directly inhibits TSC2 (Figure1.2) as well as activates ribosomal S6 kinase 
(RSK) which, in turn, phosphorylates Ser1798 of TSC2 and Ser719, Ser721, and 
Ser722 sites of raptor, ultimately resulting in mTORC1 activation (3, 8). 
1.1.3.2 Cellular energy status. Low cellular energy levels increases 
Adenosine monophosphate (AMP): Adenosine triphosphate (ATP) ratio and also 
activates Liver kinase B1 (LKB1), Transforming growth factor β activated kinase-
1 (TAK1) and Calcium/calmodulin-dependent protein kinase kinase 2 (CaMKK2) 
kinases. The various kinases activate AMP-activated protein kinase AMPK via 
phosphorylation of Thr172, AMP stabilizes this phosphorylation. Active AMPK  
phosphorylates TSC2 and raptor resulting in inactivation of mTORC1 signaling, 
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and its downstream energy consuming processes, such as translation, ribosome 
biogenesis, etc. (Figure 1.3b) (3, 8). 
1.1.3.3 Oxygen levels. Low cellular oxygen or hypoxia downregulates 
mTORC1 signaling via various mechanisms. Hypoxia leads to energy stress 
which activates AMPK. AMPK can induce regulated in development and DNA 
damage responses 1 (REDD1) expression, phosphorylate TSC2 and raptor 
resulting in mTORC1 inhibition (Figure 1.3b). Alternatively, hypoxia stabilizes 
Hypoxia-Inducible Factor (HIF1α), a transcription factor, induces REDD1 
expression which, in turn, competes with 14-3-3 to bind and activate TSC 
complex, resulting in mTORC1 inhibition. Moreover, in response to hypoxia 
proteins, such as BCL2/adenovirus E1B 19kDa interacting protein 3 (BNIP3) and 
promyelocytic (PML) leukaemia prevent Rheb/mTOR interaction, therefore, 
inhibits mTORC1 activation (3, 8). 
1.1.3.4 DNA damage stress. DNA damage stress induces sestrin 1 and 2 
expression, as a part of p53 transcriptional program. Sestrin 1 and 2 activate 
AMPK and consequently inhibit mTORC1 (Figure 1.3b) (3, 8). 
1.1.3.5 Amino-acids. Amino acids, particularly leucine has been shown to 
be essential for mTORC1 activation. Recently, Solute carrier family -7 member 
5/-3 member 2 (SLC7A5)/SLC3A2) was shown to regulate export of L-glutamine 
in exchange of import of L-leucine into the cells to maintain mTORC1 activity. 
The mechanism of amino acid-dependent mTORC1 activation is not clearly 
understood. Interestingly studies show that the amino-acid signaling to mTORC1 
is independent of TSC-complex, mTORC1 activation in cells deficient in TSC1 or 
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TSC2 responded to amino acid deprivation.  Recently, Rag family of proteins, 
comprising four small GTPases RagA through D which exist as obligatory 
heterodimers Rag A/B and Rag C/D, have been shown to regulate mTORC1 
activation in an amino-acid dependent manner (Figure1.3c).  In the presence of 
amino acids active Rag A/B-GTP and Rag C/D-GDP interacts with raptor, leading 
to co-localization of mTORC1 to Rab7-rich vesicles, also the site for Rheb, 
thereby activating mTORC1. Various studies suggest the involvement of  
Mitogen-activated protein kinase3 (MAPK3) and mammalian vacuolar protein 
sorting (Vps) 34 homologue (hVps34) in the amino-acid mediated activation of 
mTORC1 (3, 8).  
1.1.3.6 Non-classical regulatory inputs. 
 Hippo pathway. The function of the Hippo pathway is to regulate organ 
size by maintaining cell number  through inhibition of proliferation and activation 
of apoptosis. Inhibition of the Hippo pathway kinase large tumour suppressor 
homologue (LATS) hypophosphorylates   Yes-associated protein (YAP; also 
known as Yorkie homologue), resulting in nuclear translocation of YAP. Nuclear 
YAP induces expression of genes associated with proliferation and inhibits the 
expression of apoptotic genes.  It was recently shown that YAP positively 
regulates mTORC1 and mTORC2. YAP promotes expression of the microRNA 
miR-29 which, in turn, inhibits the translation of Phosphatase and tensin homolog 
(PTEN) (Figure 1.3 d). PTEN  downregulation activates PI3K pathway and 
activates  mTORC1 and mTORC2 (2, 13).  
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WNT pathway. Glycogen synthase kinase 3β (GSK3β) inhibits mTORC1 
by phosphorylation of Ser1379 and Ser1383 of TSC2, resulting in its activation. 
WNT signalling inhibits GSK3β and the TSC complex, and thus activates 
mTORC1 (Figure 1.3e) (2, 14).  
Notch signaling. Notch signalling regulates cell proliferation, 
differentiation and development. Notch signalling increases raptor protein 
expression and mTORC1 assembly, hence activates mTORC1 (2, 15). 
1.1.4 mTORC1 and cell metabolism 
mTORC1 is a cell growth and proliferation promoting pathway. It 
integrates upstream signals of nutrient availability and cellular homeostasis, as 
discussed in the previous section, to promote anabolic processes, including 
protein, lipid and nucleotide biosynthesis and inhibit catabolic processes, 
including autophagy (3, 6). Recent global ‘mTOR omics’ studies—
phosphoproteomics, ribosome profile, transcriptomics and metabolomics, have 
been instrumental in the identification of its substrates and target pathways (16-
19). 
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Figure 1.3 Upstream classical and non-classical inputs to mTORC1 are shown.  
(a) Growth factor or insulin-like growth factor receptor activates PI3K that forms 
PIP3. PIP3 activates PDK and also mTORC2. Both mTORC2 and PDK activate 
AKT which, in turn, inhibits TSC-complex, and activates mTORC1. (b) Energy 
stress, such as hypoxia and low ATP, and DNA damage stress, both activate 
AMPK which activates TSC-complex or inhibits raptor to inhibit mTORC1. (c) 
Amino acids recruit mTOR to lysosomes via RAG heterodimers. Rheb activates 
mTORC1 at the lysosomes. (d) Inhibition of the Hippo pathway activates 
mTORC1 by inhibition of PTEN (e) WNT pathway negatively regulates mTORC1 
through inhibition of GSK3β/TSC-complex axis. The model shows elaborate 
molecular connections between the above described pathways and mTORC1, 
major phosphorylation sites, and their upstream kinases in the signal 
transduction (adapted from (2), more details in text).  
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1.1.4.1 Protein synthesis. mTORC1 drives protein synthesis (Figure 1.4a). 
Infact, the two most well established substrates of mTORC1 are ribosomal S6 
kinase (S6K, also called p70S6K) and eIF4E-binding protein (4EBP).  mTORC1 
phosphorylates S6K Thr389 which, in turn,   phosphorylates ribosomal protein S6 
(a component of the 40S ribosomal subunit), increases ribosome biogenesis and, 
therefore, global protein synthesis. In addition, S6K-mediated   phosphorylation 
of eukaryotic translation initiation factor 4B22 (eIF4B22) and eukaryotic 
elongation factor 2 kinase (eEF2K), and its direct interaction with eIF3 regulate 
global translation through unknown mechanisms.  
Also, mTORC1 phosphorylates 4EBP at multiple residues, causes its 
dissociation from the eIF4E that allows eIF4G/eIF4E binding at the 5' 
oligopyrimidine tract (TOP)- and pyrimidine-rich translational element (PRTE)- of 
specific mRNAs to promote translational initiation (2, 20).  
1.1.4.2 Glucose metabolism and mitochondrial health. mTORC1 has 
been shown to upregulate expression of genes associated with glucose uptake, 
glycolysis, and pentose phosphate pathway by inducing translation of HIF1α and, 
possibly cellular homolog of the retroviral v-myconcogene  (c-Myc) (18, 21), In 
addition, mTORC1 has been shown to directly control multiple aspects of 
mitochondrial biology, including— biogenesis, quality control, DNA copy number, 
gene expression of proteins of oxidative metabolism, membrane potential, 
oxygen consumption and ATP levels  
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Figure 1.4 Regulation of metabolism by mTORC1.  mTORC1 increases overall 
anabolism and inhibits catabolic degradation by autophagy. (a)  mTORC1 
stimulates protein synthesis by directly phosphorylating S6K ad 4EBP1.(b) 
mTORC1 activates SREBPs, which upregulates gene expression of the key 
enzymes of PPP, and lipogenic pathways. In addition, mTORC1 activates CAD 
via S6K. (c) mTORC1 inhibits autophagy by targeting ULK1, ATG14, and TFEB  
(2).  
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in various studies. mTORC1-dependent regulation of PPARγ coactivator-1 
(PGC1-α) / yin-yang1 (YY1) interaction controls the transcriptional activity of 
PGC1-α that , in turn, has been implicated in regulating mitochondrial biogenesis 
and oxidative metabolism (22). In addition, mTORC1 directly interacts with and 
phosphorylates B-cell lymphoma-extra large (BCL-xL) resulting in increased 
permeability through Voltage-dependent anion-selective channel protein 1 
(VDAC1), and mitochondrial oxidative phosphorylation (23). Moreover, mTORC1 
regulates mitophagy that plays an important role in maintaining mitochondrial 
homeostasis (24). 
1.1.4.3 Nucleotide-biosynthesis. mTORC1 stimulates the expression of 
5ʹ-phosphoribosyl-1’-pyrophosphate (PRPP, a ribose moiety for nucleotide 
synthesis) via the transcription factors sterol regulatory element-binding proteins 
(SREBPs).  In addition, recently mTORC1 drives de novo pyrimidine biosynthesis 
via S6K-mediated phosphorylation of glutamine (Gln)-dependent carbamoyl-
phosphate synthase, aspartate (Asp) carbamoyltransferase, dihydroorotase 
(CAD) Ser1859 (Figure 1.4b).  
Thus, mTORC1 promotes DNA and RNA synthesis and S phase 
progression. Pyrimidine synthesis also drives translation indirectly by increase in 
ribosomal RNA and, thus ribosome biogenesis. Purine biosynthesis has not been 
directly linked to mTORC1 activation so far. Although increased guanine 
synthesis is observed under serum and amino acid fed conditions, the same was 
unaffected by acute rapamycin treatment. However, whether mTORC1 regulates 
guanine biosynthesis via a rapamycin-independent mechanism remains to be 
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investigated. It may be noted that mTORC1 prevents sirtuin 4(SIRT4, a mito-
chondrial protein) mediated ADP ribosylation and inactivation of Glu 
dehydrogenase (GDH). Thus, it may lead to higher ATP synthesis via GDH -
α-ketoglutarate (αKG, a tricarboxylic acid (TCA) cycle intermediate) pathway (2, 
17-19).  
1.1.4.4 Lipid biosynthesis. mTORC1 increases SREBP-mediated 
lipogenic gene expression by S6K-depdendent; and Lipin1, a phosphatidic acid 
phosphatase that inhibits SREBP, depdendent, S6K-independent mechanisms 
(Figure 1.4b). Increase in lipid biosynthesis produces new membranes and signal 
transduction molecules (18).  
1.1.5 mTORC1 inhibits autophagy 
mTORC1-mediated inhibition is the most well studied regulation 
mechanism of autophagy (described in greater detail in section 1.2.2).   
1.1.6 mTORC1 in cancer 
Impaired mTORC1 signaling, resulting from gain-of-function mutations of 
its upstream positive regulators— PI3K, AKT or Ras and/or loss-of-function 
mutations of negative regulators— p53, PTEN, LKB1, or TSC1/2, is common in 
various human cancers (25). Uncontrolled mTORC1 activation provides a 
substantial selective growth and survival advantage to cancer cells. Infact, it 
contributes, to varying degrees, to every aspect of tumorigenesis (25).  
 To cite a few examples, mTORC1 downstream effectors S6K and 4E-BP 
selectively promote translation of proteins associated with cell cycle progression 
(cyclin-D1) and/or survival (MCL-1) (6, 26). mTORC1 inhibits p27, cyclin-CDK2 
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inhibitor (1). mTORC1 inhibits autophagy that is a tumor suppressor pathway. In 
addition, mTORC1 activates transcription factors such as HIF1α, SREBP1, 
cMYC and PGC1α that favor angiogenesis and enable growth promoting 
metabolic adaptation in cancer cells such as increase in glycolysis, the pentose 
phosphate pathway and, lipid biosynthesis, mitochondrial homeostasis and 
upregulation of gln metabolism (2, 6).  
1.1.7 mTOR Inhibitors as anti-cancer therapies 
Given the critical importance of this pathway in human tumorigenesis, 
there has been tremendous research and clinical interest in mTOR-specific 
inhibitors (1).   
1.1.7.1 Rapalogs. Rapalogs, also known as the first generation mTORC1 
inhibitors, are derivatives of rapamycin. They are allosteric inhibitors of mTORC1 
that first bind to FKBP12, and the rapalog-FKBP12 complex then binds the FAT 
domain of mTORC1 and inhibits its activity in a kinase- independent manner 
(Figure 1.1a) (1, 27).  Rapalogs have been notably successful in otherwise 
chemoresistant cancers, particularly renal cell carcinoma and mantle cell 
lymphoma, tumors associated with TSC1/2 mutations, and have been relatively 
well tolerated in the clinic (27).  
However, the success has been limited by modest efficacy in many 
tumors, the effect of rapalogs being mostly cytostatic instead of cytotoxic (28). 
Among the identified mechanisms associated with reduced efficacy of rapamycin 
and its analogs are —the inhibitory effect on certain mTORC1 substrates, 
particularly 4E-BP1, is not that durable (29). The rapalogs fail to fully activate 
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autophagy in some cases (30). In addition, active mTORC1 negatively regulates 
AKT either directly by activation of growth factor receptor-bound protein 10 
(Grb10), which inhibits PI3K, or via S6K mediated inhibition of PI3K or mTORC2. 
Thus, mTORC1 inhibition by rapalogs causes feedback activation of PI3K/AKT 
and mTORC2/AKT axes (7). Moreover, activation of compensatory pathways 
such as MAPK is associated with mTORC1 inhibition (31).  
Given the limitations of rapalogs, there has been a lot of interest in the 
dual mTORC1/2 kinase inhibitors (TOR-KIs) and PI3K-/TOR – kinase inhibitors, 
also referred to as second and third generation mTOR inhibitors (32) 
1.1.7.2 mTORC1/2 kinase inhibitors (TOR-KIs). Their mechanism of 
action is to competitively displace ATP from the enzyme catalytic site.  Rapalogs 
cause derepression of mTORC2 by inhibiting S6K –mediated phosphorylation 
and inhibition of rictor. mTORC2, in turn, activate AKT by phosphorylating 
Ser473 of AKT. Therefore, overcoming mTORC2 dependent PI3K activation.  is 
one of the most well recognized advantage of TOR-KIs over rapalogs alone.  
 In addition, they inhibit mTORC1 more effectively. An overall outcome is, 
therefore, a more profound effect on almost every cellular aspect compared to 
rapalogs (1, 27). Greater and more durable inhibition of 4EBP1 and inhibition of 
mTORC2/AKT/glycogen synthase kinase3- β (GSK3-β) and mTORC2/protein 
kinase C (PKC) results in an enhanced inhibition of translation (27, 33).  
In addition, there is more effective inhibition of glycolysis, as AKT-
mediated activation of glucose transporter 1 (Glut1), HIF1α and, HIF2α is also 
prevented (27, 33). Also, lipogenesis is inhibited by inhibition of ATP citrate lyase 
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(ACL), a essential regulator of fatty acid synthesis, and activates GSK3-β 
mediated degradation of SREBP1 (27, 34).  
There is stronger cell cycle arrest as dual inhibition inhibits translation and 
transcription, and promote degradation of cyclins D1 and E, inhibition of 
cytoplasmic translocation of p27 causes cyclin-CDK2 inhibition and also 
decreases actin stability by inhibiting p27-RhoA binding (27, 35). TOR-KI 
inhibitors also induce apoptosis, unlike rapalogs, due to compromised anti-
apoptotic function of AKT (27, 36). 
1.1.7.3 PI3K-mTOR dual kinase inhibitors (PI3K/TOR-KIs). Although 
inhibition of mTORC2 by TOR-KI inhibits Ser473 and hence full activation of 
AKT, modest, substrate-dependent activity of AKT is still maintained through the 
PI3K/ PDK1-mediated phosphorylation of Ser308. This results in compromised 
efficacy of TOR-KIs, and at the same time stimulated the interest in dual PI3K-
mTOR kinase inhibitors. 
The advantage of these dual inhibitors is that they inhibit S6K mediated 
derepression of AKT phosphorylation at Thr-308 by PI3K/PDK1 axis as well as 
AKT-Thr473 phosphorylation by mTORC2/AKT. These PI3K/TOR-KIs are 
potentially more effective in the inhibition of tumor growth and survival, given 
their multifold ability to target key kinases activating oncogenic pathways, 
including lipid and protein biosynthesis, cell cycle and cell growth, survival, 
metastasis and angiogenesis (1, 5, 27).  
While such strategies are expected to improve the clinical efficacy, given 
the overwhelming networking of mTORC1, efforts are needed to develop better 
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strategies to effectively exploit this pathway in the clinic. Thus, investigation of 
the most “vulnerable" signaling pathway(s) in a given disease setting, not 
necessarily upstream or parallel, but also downstream of mTORC1 should be 
addressed. The future expects to see in the clinic mTORC1 inhibitors effectively 
combined with inhibitors of such “vulnerable” pathways. 
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1.2 Overview of autophagy 
C de Duve coined the term ‘autophagy’ in 1963, meaning ‘self-eating’ in 
Greek, which refers to lysosomal degradation of cytoplasmic content by the cell 
(37). There are three types of autophagy: macroautophagy, microautophagy and 
chaperone-mediated autophagy (38). This study focuses on macroautophagy, 
henceforth referred to as autophagy.  
The characteristic feature of autophagy is formation of a double-
membrane structure called autophagosome that sequesters cytoplasmic 
components, including proteins, and organelles such as mitochondria, and 
targets them for lysosomal degradation (38-40). The process involves a set of 
proteins designated as ATG or ‘autophagy-related’ proteins, over 30 of which 
have been identified so-far (38, 40). Enormous progress has been made in 
understanding the regulatory mechanisms and overall biology of ATG proteins 
over the past 30 years, however, there are still questions. For example—
alternative autophagy is known to occur independent of the ‘so-called’ essential 
autophagy genes (described in detail in section 1.2.1), including UNC-51-like 
kinase 1 (ULK1/2), beclin1 (BECN1), ATG-5,-7, even LC3 (41, 42). Which 
compensatory proteins or mechanisms fulfill the job in their absence is not clear?  
Further, autophagy is an evolutionary conserved pathway of degradation 
and recycling that plays a very important role in maintaining physiological 
homeostasis in response to cellular oxygen, nutrient and hormonal demands 
(43). Under stress and starvation conditions, levels of autophagy increase, 
leading to removal of damaged proteins and organelles, and breakdown of lipids 
26 
 
and proteins in the process supports cellular metabolism by providing amino 
acids, acetyl-CoA and fatty acids (44). In the context of cancer on one hand the 
mice lacking ATG4C, ATG5, ATG7 UVRAG, and Bif1, and BECN1 are prone to 
tumors (45), on the other hand puncta of key component of autophagosomes- 
LC3 were highly overexpressed almost universally in advanced solid tumor 
human specimens (46). Thus, whether to induce or inhibit autophagy in cancers 
is an important question in the field.  
By management of cellular stress, removal of deleterious cellular 
components and maintaining cellular homeostasis, autophagy inherently is an 
anticancer pathway. And, prolonged and excessive autophagy can lead to cell 
death (47). However, unlike apoptosis and necrosis, autophagy doesnot commit 
a cell to death. Due to its reversible nature the highly autophagic cells that 
sustain through a stress can quickly degrade autophagic vesicles, and grow 
exponentially as soon as the stress is removed. (48). And ultimately hijack 
autophagy pathway to support their aberrant cancer metabolism and growth (49). 
Thus, depending on the context autophagy can have dual consequences.  
The very first results of the clinical trials of inhibitors of autophagy alone and in 
combination therapy, in various advanced stage cancers have been published 
recently, and they sound promising 
(https://www.landesbioscience.com/journals/autophagy/toc/volume/10/issue/8/). 
However, more work is needed in this direction, including—which cancer stage or 
type patients and which drug combinations will benefit from induction or inhibition 
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of autophagy; development of safer and autophagy specific modulators, etc. 
(https://www.landesbioscience.com/journals/autophagy/toc/volume/10/issue/8/). 
Thus, the cross-talk between autophagy and cancer cell death and 
survival mechanisms is not clear, but there is an intricate connection. 
Understanding the precise mechanisms involved in interplay between these 
processes will provide exciting opportunities to target cancer and drug 
resistance.  
1.2.1 The core autophagy molecular machinery 
The autophagy pathway comprises 6 different steps, representing different 
stages in the formation of autophagosome (Figure 1.5 top). The autophagy 
induction signal is followed by the assembly of ATGs at the phagophore 
assembly site or omegasomes (in mammals, phosphatidylinositol 3-phosphate 
(PI3P)- zinc finger FYVE domain-containing protein 1 (DFCP1) tagged regions 
located on the ER membrane). The ATGs, specific soluble N ethylmalemide 
sensitive factor attachment protein receptors (SNAREs) and, other tethering 
factors then participate in a coordinative fusion of membranes derived from 
plasma-membrane, Golgi, and endosomes. This subsequently gives rise to cup-
shaped initial membrane structure called phagophore that surrounds cytoplasmic 
contents to be degraded. Phagophores then expand and ultimately close at their 
ends to give rise to double membrane structures called autophagosomes. 
Autophagosomes ultimately fuse with the lysosomes and give rise to 
autolysosomes, which, along with their contents, are subsequently degraded and 
recycled (40). 
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Each step is associated with a distinct functional ATG protein complex, as 
such six ATG functional units have been described (38, 50) (Figure1.5 bottom).  
1.2.1.1 The first step is induction. The most upstream event in 
autophagy is activation of the ULK1, a yeast Atg1 homolog, complex (51). The 
ULK1 complex consists of ULK1, a Ser/Thr kinase that interacts through its C 
terminal domain, with FIP200 (also known as RB1CC1 or ATG17), ATG13L, and 
ATG101. These interactions are required for the stability and kinase activity of 
ULK1 (51).  Activation of the ULK1 complex results in a net dephosphorylation of 
this complex, ULK1 autophosphorylation, phosphorylation of ATG13 and FIP200, 
and recruitment of ULK1 to the phagophore membrane and autophagy induction 
(51). 
 It is implicated in induction and maturation of the autphagosome. In 
addition to its  role in the autophagosomal membrane  localization of ATG9a (51), 
the recent studies have shed light on  some of its downstream substrates, 
including—BECN1, AMBRA1, (involved in vesicle nucleation as described 
below), and DAPK3 (zipper interacting protein kinase) (52).  
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Figure 1.5 Step-wise depiction of autophagy pathway, molecular machinery 
involved. Small molecule and genetic modulators of various steps are indicated 
with red ovals and blocking arrow towards the step they inhibit. (Top)Various 
stages in autophagosome formation are depicted. (Bottom) Molecular Details 
associated with each stage of autophagosome formation are shown. (1)Inhibition 
of mTORC1 induces induction of autophagy by ULK1 complex activation, (2 and 
2’) Nucleation of phagophore requires activation of ULK1 and BECN1/VPS34 
complexes. The BECN1/VPS34 complex has three forms, depending on what 
are the interacting partners of the core BECN1/VPS34/VPS15- Atg14L and 
UVRAG association induce autophagy. In contrast, the Rubicon complex 
negatively regulates this complex. (3) Elongation to form complete closed, 
souble-membrane membrane structure, autophagosome, requires ATG12-ATG5-
ATG16 and LC3-PE ubiquitination-like conjugation systems. ATG4 is a protease, 
ATG7 is E1-like, ATG3 and ATG10 are E2-like, and ATG12-ATG5-ATG16 is E3-
like enzyme complex.  (4 and 4’)The production of PI3P by the (BECN1-VPS34) 
complex recruits phospholipid-binding proteins, including ATG9, ATG2, WIPI1/2 
(or ATG18), which function to recruit lipids to the phagophores. (5 and 5’) 
Autophagosome fuses with lysosome to form autolysosome, where degradation 
takes place. LAMP1/2, Rabs, dynein are needed for the process. (6 and 6’) 
Lysosomal hydrolases, Cathepsins -D,-L, and -B hydrolyse the autolysosomal 
content, and the products as well as lysosomes are recycled (adapted from (38, 
53). 
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(PI3K) complex, also known as the BECN1- vacuolar protein sorting 34 (BECN1-
VPS34) complex (50). The core BECN1-VPS34 complex comprises VPS34, the 
catalytic PI3K; VPS15 (or PIK3R4), a Ser/Thr kinase that regulates the function 
of VPS34; and BECN1 (or ATG6), a BH3-domain containing protein that acts as 
an adaptor protein (50). Association of additional proteins with these 3 core 
protein components regulates the function of this complex (54): 
ATG14 is essential for the recruitment of VPS34 to the phagophore, 
therefore, the core complex containing ATG14 containing BECN1-VPS34 
complex is specific to autophagy(55);  
Activating molecule in BECN1-regulated autophagy (AMBRA1) is 
involved in nutrient dependent localization of VPS34 to the phagophore (56);  
UV Radiation Resistance-Associated Gene  (UVRAG) is never found in 
vesicles containing ATG14, occurs in late endosomes, therefore, contributes to 
formation of autophagosome and maturation by contributing to autophagosome-
lysosome fusion(55);  
Bax-interacting factor 1 (Bif-1) promotes UVRAG binding to the core 
complex(57);  
RUN domain and cysteine-rich domain containing, BECN1-
interacting (Rubicon) inhibits UVRAG-containing complexes, therefore, 
UVRAG/Rubicon containing complexes negatively regulate autophagosome 
maturation (58);  
BCL-2 family proteins (BCL-2, BCL-xl, MCL-1) inhibit the VPS34-
BECN1 complex (59). 
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The production of PI3P by the (BECN1-VPS34) complex is critical to 
recruit phospholipid-binding proteins, including: (i) Vacuole Membrane Protein 1 
(VMP1) and  (ii) ATG9: transmembrane proteins cycling between the 
autophagososmes, Golgi and endosomes, and function to recruit lipids to the 
phagophores(60); (iii) WD-repeat-interacting phosphoinositide protein 1/2 
(WIPI1/2) and ATG2: play a role in recruiting ATG9 from autophagosome to 
peripheral mambranes; and (iv) DFCP1: perform an important but yet unknown 
function in autophagy (60, 61). Also recently, the PI3P generation was shown to 
be critical for the stabilization of ULK1 complex at the omegasome (40).  
1.2.1.3 Vesicle expansion and completion. Next, step is the expansion 
of the initial membrane structure called phagophore to form a double membrane 
vesicle called autophagosome (40). The process involves two ubiquitin-like 
conjugation systems— ATG12-ATG5-ATG16L system and the microtubule-
associated protein 1-light chain 3 (LC3 or ATG8) phosphatidylethanolamine (PE) 
conjugation system(50, 62-65). ATG12, a ubiquitin-like protein, and ATG5 are 
conjugated to each other with the help of ATG7 and ATG10 i.e. an E1-like 
activating and an E2-like conjugating enzyme, respectively. ATG12-ATG5 then 
bind ATG16L (ATG16-like) that gives rise to a multimeric (ATG12-ATG5-
ATG16L) complex (50). 
LC3 is first processed at its C terminus by ATG4, a cysteine protease, that 
exposes its C-terminal glycine residue to form LC3I (66, 67). LC3I is then 
converted from unconjugated, cytoplasmic form to PE-conjugated, membrane 
bound form called LC3II with the help of ATG7 and ATG3 i.e. an E1-like 
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activating and an E2-like conjugating enzyme, respectively(50). ATG12-ATG5-
ATG16L complex is the E3 ligase for this reaction(68) . As the membrane closes 
to form complete autophagosome, ATG12-ATG5-ATG16L leave the 
autophagosome and LC3-PE still remains and is needed for the closure of the 
autophagosomal membrane(50).  
Conversion of unconjugated, cytoplasmic LC3I to PE-conjugated, 
membrane (autophagosomes and autolysosomal) bound LC3II is the gold 
standard marker of autophagy. By immunofluorescence labeling of endogenous 
LC3 or imaging LC3 fused to fluorescent proteins such as GFP, cytoplasmic LC3 
appears as diffused form while membrane bound LC3 appears as distict puncta. 
By immunoblotting analysis, LC3I appears as a 18 kDa while LC3II appears as a 
16 kDa band, the two forms are easily separable using 12-15% SDS-PAGE. 
1.2.1.4 Vesicle Maturation (fusion with lysosomes). After completion of 
autophagosome formation, autophagosomes fuse with lysosomes to form 
autolysosomes. The exact mechanism is unclear, however, the process seems to 
depend on several proteins, including —  SNAREs, Ras  like in rat brain (Rab), 
Endosormal sorting complex required for transport (ESCRT), homotypic fusion 
and protein sorting (HOPS), LAMP2, LC3-PE, and  the Rubicon- UVRAG 
complex (69, 70). 
1.2.1.5 Degradation, recycling and termination. Ultimately the cytosolic 
contents within autolysosomes are degraded with the help of lysosomal 
hydrolases and lipases. LC3II is recycled back to the cytosol by ATG 4 mediated 
cleavage of LC3-PE (66).  
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Moreover, degradation of autolysosomal contents re-activates mTORC1 
which, in turn, terminates autophagy and also leads to formation of proto-
lysosomal tubules and vesicles. Ultimately the lysosomal content of the cell is 
restored (71). 
Autophagy can be both non-selective leading to bulk disintegration of 
cytoplasmic components as well as selective, targeting specific substrates such 
as proteins, lipid droplets, and organelles for degradation. For selective 
autophagic degradation, targets are tagged with ubiquitin (or other signals, in 
case of lipids). The target is then recognized and delivered to autophagosomes 
by autophagy cargo receptors such as sequestosome (SQSTM1, also called 
p62), Nix, Nuclear Dot Protein 52 (NDP52), and Neighbor of BRCA1 gene 
(NBR1) which interact with ubiquitin on target on one side, and with LC3, through 
LC3-interaction (LIR) domain on the other side. During autophagic degradation of 
the target, the cargo receptors also are degraded, hence p62 degradation is 
often used as a marker of autophagic flux (72). 
1.2.2 Regulation of Autophagy 
Any form of cellular stress, including growth factor, nutrient, oxygen, and 
DNA damage, induces autophagy (Figure 1.6). The various mechanisms, 
including regulation of autophagy gene expression, post translational 
modifications, important upstream regulatory proteins have been described 
below: 
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1.2.2.1 Phosphorylation. 
mTORC1. The most widely studied regulator of autophagy is mTORC1. 
Under nutrient replete or stress-free conditions, active mTORC1 inhibits 
autophagy. mTORC1 regulates autophagy by direct phosphorylation and 
inhibition of (52):  
(1) the ULK1 complex components—ULK1 (Ser758), ATG13 (site yet to 
be determined);  
(2) ATG14 (Ser3, Ser223, Thr233, Ser383 and Ser440), an essential 
component of autophagic VPS34 kinase complex;  
(3) death-associated protein 1 (DAP1, Ser3, and Ser51) that prevents the 
activity of ULK1 or VPS34 complexes; and  
(4) transcription factor EB (TFEB, that controls genes required for 
autophagy and lysosome biogenesis) (Ser142, Ser211) leading to it its 
cytoplasmic accumulation, and  inhibition of autophagy.  
mTORC1 is inhibited in response  to starvation of amino acids, growth 
factors, nutrients, and DNA damage response which, in turn, results initiation of 
autophagy. In general, nutrient starvation in the cells inhibits mTORC1 and 
activates autophagy. As autophagy restores nutrients, mTORC1 is reactivated 
which, in turn, acts to terminate autophagy. Among the proposed mechanisms, 
mTORC1 reactivation initiates generation of tubular proto-lysosomes leading to 
reformation of lysosomes which terminates autophagy.  In another study, TFEB 
is recruited to lysosomes by Rag GTPases where it is phosphorylated by 
mTORC1 and results in autophagy inhibition (2). 
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Figure 1.6 Networking between cellular stress sensors and autophagy. Three 
main stress sensors (indicated in red boxes)- mTORC1, AMPK, ER stress  
coordinate protein synthesis in response to cell’s growth factor, oxygen, nutrient, 
and genomic homeostasis. Growth factor signaling inhibits autophagy via 
RTK/PI3K/AKT/mTORC1 pathway.  Energy stress induces autophagy via AMPK, 
and via AMPK/mTORC1 pathway. Hypoxia induces autophagy via energy stress 
dependent activatation of AMPK or via REDD1/mTORC1 pathwayAmino acid 
starvation activates autophagy via RAG/mTORC1 pathway. DNA damage stress 
activates induces p53/AMPK dependent autophagy.Finally, ER stress activates 
autophagy via IRE1/JNK and PERK/eIF2α pathways. Recently ER stress has 
been shown to inhibit mTORC1. 
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AMPK. In addition AMPK, which is activated in response to energy 
starvation, hypoxia, and DNA damage, also positively regulates ULK-1 complex 
by either inhibition of mTORC1 or direct phosphorylation and activation of ULK-1.   
Under glucose starvation condition, AMPK was shown to directly phosphorylate 
BECN1 and stimulate PI3K complex formation, which promoted autophagy (73). 
DAPK/JNK/ERK. In the absence of activating stimuli BECN1 is 
sequestered and inhibited by BCL-2 family proteins, such as BCL-2, BCL-Xl, 
MCL-1; 14-3-3 or vimentin, intermediate filament (IF) protein (53). 
Phosphorylation by tumor suppressor death-associated protein kinase (DAPK) at 
Thr119 of BECN1; and/ or by the c-Jun N-terminal kinase (JNK) and ERK of 
BCL-2 leads to dissociation of the inhibitory BECN1-BCL-2 complex(74-76). 
Subsequently, BECN1 associates with the PI3K complex and promotes 
autophagy. Recently, phosphorylation of BECN1 by protein kinase B (PKB) has 
been implicated in inhibition of autophagy by promoting BECN1-14-3-3 and 
BECN1-Vimentin protein complex formation (77). In addition, BECN1-VPS34 
complex activity is regulated by post-translational modifications, including 
phosphorylation and ubiquitination (54). 
CDK1. Autophagy is suppressed during cell cycle by the cyclin-dependent 
kinase-1 (CDK1) mediated direct phosphorylation of VPS34 at Thr159(78). 
PKA-, PKC-, CK-. Recently, PKA- or PKC- mediated phosphorylation of 
LC3 II was shown to inhibit autophagy by an unknown mechanism(79). 
Phosphorylation of p62 at Ser403 by the casein kinase strengthens its binding 
with the ubiquitinated targets (80).   
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1.2.2.2 Acetylation. ULK1 is activated by acetylation by TIP60 in GSK-
dependent manner under growth factor deprivation (81, 82). Also, acetylation by 
TIP60 is known to stimulate LC3-PE conjugation by increasing ATG3/LC3 
binding (83). Moreover, deacetylation of autophagy proteins, ATG12, ATG5, 
ATG7 and LC3 by SIRT1 (84) and their acetylation by the p300 acetyltransferase 
(85) was shown to regulate autophagy under starvation and nutrient-rich 
conditions, respectively.  
1.2.2.3 Ubiquitination. Ubiquitination has been implicated in HSP90-
CDC37 mediated regulation of ULK1 and stabilization of ATG13 by ULKI/2 and 
C12orf44 (86, 87). TNF receptor associated factor-6 (TRAF-6) mediated 
ubiquitination of BECN1 has been shown to enhance its oligomerization and 
promote autophagy. The same study identified deubiquitinating enzyme A20 as a 
negative regulator of BECN1 mediated autophagy(88). Overall, the activity of the 
core BECN1-VPS34 complex depends on its differential interacting partners 
(described in section 1.3.1.2 in more details). These post translational 
modifications, in fact, regulate affinity of the various protein partners towards the 
core complex and vice versa. 
1.2.2.4 Regulation of Gene expression. In addition to TFEB dependent 
regulation of autophagy genes, E2Fs-1, -2 and -3 were shown to directly bind 
and upregulate the expression of various autophagy genes, including BECN1 
(54); (89, 90). NF-kB has also been shown to upregulate BECN1 mRNA levels 
and positively regulate autophagy (54, 91). Moreover, miR-30a has been 
reported to negatively regulate BECN1 expression (92).  
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1.2.3 Autophagy in cancer 
Normal cells depend on constitutive autophagy to maintain metabolic 
homeostasis and protein and organelle quality control(93). In cancers, depending 
on their stage and genetic context, autophagy can have multifunctional effects 
i.e. cell death or survival. 
1.2.3.1 Autophagy as a tumor suppressor mechanism. In support of a 
tumor suppressor role of autophagy, mice deficient in autophagy proteins—
ATG4C, ATG5, ATG7 UVRAG, and Bif1 are prone to tumors (45). Also, 
activation of oncogenic pathways such as PI3K/AKT /mTORC1 or onco-proteins 
such as BCL-2 causes inhibition of autophagy (52, 53). The proposed 
mechanism(s) for the role of autophagy in tumor suppression include (Figure 1.7) 
— 
Elimination of ROS. Elimination of ROS by clearing impaired mitochondria 
(94, 95); by p62 dependent mechanisms of regulation of anti-oxidative gene 
expression, including p62/KEAP/NRF2 axis, nuclear factor-κB (NF-κB), and 
TRAF-6 complex formation (49, 96, 97).  
Anti-inflammatory mechanism. Intrinsic cellular defense against 
degenerative inflammation, e.g. by inhibition of necrosis, both necroptosis and 
PARP- mediated cell death (98). (99-101).   
P62 degradation. It allows degradation of p62, and, therefore, inhibits 
oncogenic NF-kB, NRF2, and caspase-8 aggregation and activation, thus 
preventing inflammation and tissue injury. (101, 102).  
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Maintenance of genomic stability. Restrains chromosomal instability and 
aneuploidy by mechanisms, including by functioning as a protein and organelle 
quality control mechanism, it ensures  preventing defacement of cellular proteins 
associated with critical cellular processes, including DNA replication, cell division, 
DNA repair, etc., and hence occurrence of DNA damage and mutagenesis 
ultimately resulting in tumorigenesis (101, 103). In addition, vital cellular 
processes, including DNA replication, transcription, mitosis consume energy, 
therefore, autophagy functions to ATP availability by maintaining mitochondrial 
health (101).  
Promotes oncogene induced senescence. Oncogene-induced senescence 
In Ras-induced IMR90 senescent fibroblasts autophagy-mediated protein 
turnover was shown to be coupled simultaneously to the production of pro-
senescence cytokines, IL-6, IL-8 (104). 
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Figure 1.7 Differential role of autophagy in regulating cell survival in neoplastic 
cells versus established tumors. In normal cells, autophagy functions as a cell 
intrinsic tumor suppressor mechanism by removal of damaged organelles, 
mitigating deleterious ROS, thus limiting chromosomal instability and mutations, 
promotes oncogene-induced senescence. In addition, it contributes to effective 
immune surveillance, by directly regulating immune cell functions. However, 
eventually tumor cells hikack autophagy pathway and use it for their own benefit, 
combat metabolic stress, hypoxia, ER stress. Thus, in established tumors it 
promotes cancer cell survival. 
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1.2.3.2 Prosurvival role of tumor autophagy. In contrast, there is 
substantial evidence in support of prosurvival role of tumor autophagy (49, 105). 
In a recent investigation using immunohistochemical staining in advanced solid 
tumor human specimens, LC3 puncta were moderate to highly overexpressed 
almost universally (46). The proposed mechanism(s) for the role of autophagy in 
tumor progression (Figure 1.7) — 
Autophagy is a robust cellular response to various stresses, including limited 
oxygen, nutrient availability, and the endoplasmic reticulum (ER) stress (44), 
which facilitates survival during cancer progression in cells with defective 
apoptosis (105).  
Starvation. The oncogene-induced cancer growth and proliferation poses a 
high metabolic and energy demand on the cancer cells, resulting in metabolic 
stress(106). Under metabolic stress, autophagy provides for metabolites and 
energy by recycling proteins and organelles. Ras activation in cancer cell lines 
increases basal autophagy, and causes addiction of cells to autophagy under 
starvation conditions and tumor growth (43). ROS signaling is an important 
regulator of starvation-induced autophagy (107, 108). In addition, impaired ATP 
synthesis activates AMPK which, in turn, activates autophagy(6). Recently, miR-
376b was shown to regulate starvation-induced autophagy by directly regulating 
ATG4C and BECN1 levels (109).  
Hypoxia. In addition to starvation, the tumor microenvironment is often 
hypoxic which, in turn, favors altered tumor cell metabolism, increased 
invasiveness and therapy resistance. Autophagy plays an important role as a 
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cancer cell defense against metabolic stress(110). Hypoxia activates hypoxia-
inducible factor-1 alpha (HIF-1α, a transcription factor that regulates genes 
involved in  adaptation to hypoxia)  which, in turn, induces the BH3-only protein 
Bcl-2/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) and the related 
protein, BNIP3L (111). BNIP3 and BNIP3L induce autophagy by displacing 
BECN-1 from the BECN1-BCL-2 complex(112). Activation of AMPK is another 
mechanism of autophagy induction that functions independent of HIF-1α (113).  
The unfolded protein response (UPR). is another hypoxia-induced signaling 
pathway that activates autophagy in an HIF-1-α independent manner. UPR 
activates autophagy via—PKR-like ER kinase (PERK)/ eukaryotic initiation factor 
2α (eIF2α)/ activating transcription factor 4 (ATF4); Ire1/TRAF2/JNK; 
Ca2+/CaMKK-β/AMPK dependent mechanisms (101). 
Taken together, an emerging hypothesis is that in primary cells autophagy 
functions as a tumor suppressor process by maintaining mitochondrial function 
and combating oxidative stress, mitigating inflammation and counteracting DNA 
damage and genetic instability. However, activation of autophagy beyond cellular 
threshold can lead to cell death (47). However, unlike apoptosis and necrosis, 
autophagy is not always a cell death committed pathway. If a cell lives through 
stress, autophagic vesicles are cleared-off, and infact taken-over to support 
aberrant cellular growth. Very rightly put in words by the authors, ‘Autophagy, 
stress, and cancer metabolism: what doesn't kill you makes you stronger’. 
(49).Thus, it promotes cancer cell survival in established tumors by alleviating 
stress due to—nutrient starvation, hypoxia, chemotherapy (40, 49).  
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1.2.4 Autophagy in anti-cancer therapy  
Treatment with anticancer therapies, including targeted cancer therapies 
(inhibitors of the PI3K/Akt/mTOR pathway), cytosolic or histone deacetylase 
inhibitors (sirtuin-1, HDAC1, HDAC2, and HDAC6), activators of AMPK 
(metformin), BH3-mimetics (e.g. ABT-737, obatoclax), DNA damaging agents, 
e.g. IR, doxorubicin, etoposide, temozolomide, proapoptotic soluble protein 
ligand (TRAIL), imatinib, arsenic trioxide, induce autophagy (114)). Autophagy 
induction in response to chemotherapy can have dual consequenses in cancer 
treatment, as described below. Consistently, inhibition of autophagy has been 
reported to increases as well as decrease cell death in response to anticancer 
treatments (114) 
1.2.4.1 Autophagy inhibition in anticancer therapy. Autophagy has 
been well accepted as a mechanism of drug resistance- in response to 
anticancer treatments. It promotes the maintenance of cancer stem cell 
compartment or by contributing to recovery of the cancer cells by facilitating 
recycling of chemotherapy-induced damaged organelles and protein aggregates, 
generation of energy and nutrients to promote rapid proliferation of cancer cells, 
and sustains dormancy (47, 115).  
Currently there are over 30 clinical trials using autophagy inhibitors, the 
first results of 6 of them using HCQ in combination with standard therapies in 
multiple aggressive cancers, including — glioblastoma, melanoma, lymphoma 
and myeloma, renal and colon cancers were recently released, and show 
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potential safety and efficacy in this approach 
(https://www.landesbioscience.com/journals/autophagy/toc/volume/10/issue/8/). 
Inhibitors of autophagy have been particularly promising in combination 
with therapies that are known to stimulate protective autophagy as a side effect. 
An interesting example is that of Tyrosine kinase inhibitors (TKIs), e.g. imatinib, 
which is the main treatment for chronic myeloid leukemia (CML). The TKIs are 
known to induce autophagy, probably through the inhibition of mTORC1 pathway 
which, in turn, would confer protective effects on CML stem cells, which leads to 
disease relapse following discontinuation of therapy. Pharmacological or genetic 
inhibition of autophagy in this case enhanced the efficcacy of imatinib in cell lines 
as well as primary CML cells and, resulted in near complete eradication of CML 
stem cells(116). Similarly, PI3K/mTOR inhibition using NVP-BEZ235 was shown 
to induce apoptosis and protective autophagy in renal cell carcinoma, therefore, 
combination of autophagy inhibitors with NVP-BEZ235 led to better efficacy 
(117).  
1.2.4.2 Autophagy activation as an anticancer therapy. While 
substantial evidence exists in support of autophagy as a drug-resistance or a 
prosurvival mechanism, contrasting reports show autophagic cell death in 
response to cancer therapy. Importantly, Akt/mTORC1 signaling pathway, that is 
constitutively active in many cancer cells, is the most well recognized negative 
regulator of autophagy suggesting inhibition of autophagy as a potential 
tumorigenic mechanism in those cases (7, 77). Additionally fasting, well-known to 
48 
 
stimulate autophagy, was recently reported to enhance the efficacy of 
chemotherapy in animal models (116).  
The proposed mechanism(s) underlying autophagy dependent cancer cell 
death include, excessive autophagy could be detrimental because of 
overcrowding of autophagic vesicles, or extravagant self-destruction by the cells 
(118); autophagic cell death has been demonstrated to become active under 
oncogenic stress, eg HRAS transformation (119). Also, Aurora kinase inhibition 
induces autophagic cell death in Myc transformed cell lines (116). Moreover, 
autophagy has been directly regulating stability of tumor suppressor proteins 
such as p53. BECN1 was recently shown to enhance p53 stability via USP10 
and USP13, two de-ubiquitinating enzymes .Consistently, Beclin1+/− and p53+/− 
mice show strikingly similar tumor spectra (120, 121).  
Overall while on one hand the results of inhibition of autophagy in clinical 
trials show potential in aggressive cancers, the potential in autophagy activation 
as an anticancer therapy is also being envisaged. This apparently contradictory 
role of autophagy as both a prosurvival and prodeath mechanism reflects 
heterogeneity of cancer, and points to the very complexity of the disease. It also 
presents an opportunity of feasibility of targeting different, sometimes even 
opposite, features of cancer biology.  
Notably, given the regulation of multiple cellular aspects by autophagy, the 
overall outcome of autophagy activation are bound to be cellular context 
dependent. Moreover, the magnitude and length of autophagy stimulation by an 
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intervention may give rise to alternative consequences, e.g. Over-induction may 
simply eat-up the cell, resulting in cell death.  
More detailed studies are required to uncover the complex interactions 
between autophagy and other prosurvival, as well as cell-death pathways. The 
molecular signature or pathways of contexts, such as metabolic status, specific 
oncogenic pathway activation status, etc. associated with cell death or 
prosurvival autophagy need to be carefully determined and documented.  
1.3 An overview of CLL and Flu resistance mechanisms 
Chronic lymphocytic leukemia (CLL) is the most frequent type of leukemia 
in the Western world, known to affect mainly elderly individuals (122). However, 
about one-third of the patients are below 60 years of age at the time of diagnosis 
and, in addition, progressive population obsolescence in many countries 
suggests that it could be more frequent in the future (122, 123). The disease is 
characterized by an accumulation of CD5/CD19/CD23 + B cells in the peripheral 
blood and bone marrow, which are immune-incompetent and neither differentiate 
into mature B-cells nor undergo apoptosis(122, 123).  
This malignancy has been known to follow a remarkably heterogenous 
course in terms of overall survival, symptoms, as well as response to 
therapy(123). With the increasing understanding of the disease, the more 
aggressive form or short survival times  have been more consistently observed in 
patients with unmutated V-gene, higher expression of β-2-microglobulin, CD38 
and ZAP-70 (and more recently to methylation status of ZAP-70), as well as 
aberrations in chromosome 12, 13q14, 14q32, 11q, 17p, and 6q (123). However, 
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there are no markers in the field to predict treatment effectiveness, even in the 
patients with aggressive form of the disease. Therefore given its complex 
biology, CLL is still an incurable disease. 
Currently fludarabine (Flu) a purine analog, is used as a frontline therapy 
for CLL either alone or in chemoimmunotherapy combination with 
cyclophosphamide and rituximab (124).  Flu is known to induce cell death in both 
quiescent and proliferating cells by multiple mechanisms such as incorporation 
into DNA, inhibition of DNA/ RNA synthesis and inhibition of DNA repair, etc 
(125). Although Flu-based regimens have been greatly successful in improving 
the overall outcome in CLL patients, primary or acquired resistance limits the 
effictiveness of this therapy especially in the ultra high-risk group Gribben and 
O'Brien 2011).  
Unfortunately, Flu-refractory patients are resistant to most other 
chemotherapies (126). And, the available limited treatment options for such 
patients have their own drawbacks, for example alemtuzumab (the anti-CD52 
antibody) is associated with either short-term response or no effect in many 
patients, flavopiridol (broad cyclin dependent kinase inhibitor) demonstrated 
<50% response rates in clinical trials (126). Thus, a detailed mechanistic 
understanding of such resistance at the molecular level is urgently needed for the 
rational development of appropriate alternative or combination therapies in the 
clinic.  
According to our current understanding, poor response to Flu has been 
associated with biochemical alterations associated with cellular uptake and drug 
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metabolism, including those in nucleoside transporters (human concentrative 
nucleoside transporter, hCNT3) , deoxycytidine kinase, and 5'-nucleotidase CN-II 
activities, activation of DNA repair pathways such as nucleotide excition repair, 
deregulated cell cycle checkpoints and defective apoptosis attributed to p53 
abnormailities (17p deletion, TP53 mutation) (127) and more recently with 
changes in the levels of miRNAs (miR- 34a, miR-21, miR-222, miR-148, etc.) 
(128). While p53 defects seem to be central to Flu-refractoriness, current 
prognostic models, however, fails to predict therapy response in almost half of 
the patients. Predicting non-response is a major focus of current research (129). 
 Recently, aberrant activation of B-cell receptor (BCR)-associated 
signaling pathways, and cues from the microenvironment have been implicated 
in B-cell malignancies and their poor response to chemotherapies, including CLL 
(130). mTORC1 is a critical component of BCR signaling pathway that integrates 
upstream tumorigenic stimuli to downstream  growth promoting effector pathways 
(131, 132). Inhibition of BCR associated signaling pathways, including mTORC1, 
has been identified as a potential target in B cell malignancies, including CLL 
(126). Nevertheless, mTORC1 inhibitors failed to induce significant apoptosis of 
either cycling or quiescent cells and showed so far modest clinical responses 
associated with toxicity (12). 
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1.4 Significance and Specific Aims 
Fludarabine (Flu), a purine analog, is indicated in the treatment of Chronic 
lymphocytic leukemia (CLL), the most common form of leukemia in the Western 
world.  Although Flu-based regimens have been successful in improving the 
overall outcome in patients, primary or acquired resistance is a significant 
problem. Inhibition of BCR associated signaling pathways, including mTORC1, is 
a potential target in B cell malignancies, including CLL.  However, mTORC1 
activation status per se has never been studied in the context of CLL or Flu-
responsiveness. In addition, allosteric inhibitors of mTORC1 are modestly 
effective in the clinic, as they also block feedback inhibition of the upstream PI3K 
pathway.  
In order to examine the mechanism of acquired resistance against 
Flu, Flu-resistant (FluR) B-cell lines derived via chronic exposure of Nalm-6 and 
Reh pre B Acute lymphocytic leukemia (ALL) cell lines have been used model 
system. The significant findings have been extended to Mec-2 and Mec-1, CLL 
derived cell lines, and primary CLL cells.  
We show that p-p70S6K (T389), a marker of mTORC1 activation, 
predicted Flu response in a panel of cell lines and primary CLL cells, however, 
mTORC1 inhibition produced meager cell death and did not enhance the efficacy 
of Flu. 
In an effort to investigate strategies to effectively exploit mTORC1 
addiction in cancers, we hypothesized that ‘Targeting downstream functions of 
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mTORC1 will bypass the undesirable feedback signaling events and, therefore, 
be more effective than the mTORC1 inhibition itself. To test our hypothesis, we 
investigated the following specific aims: 
AIMI. To study and target metabolic consequences of mTORC1 
activation in FluR cells.  
For cancer cells, to sustain tumor growth and survival, an essential 
requirement is to maintain nutrient and energy supply. Therefore, activation of 
oncogenic pathways, including mTORC1, must induce profound metabolic 
dysregulation to meet increased metabolic demand of the growing cancer cells 
(16, 133, 134). So, we investigated the metabolic consequences of mTORC1 
activation in FluR cells aiming to identify their selective vulnerability to 
interference with specific metabolic pathways.  
We present data showing that mTORC1 activation leads to metabolic re-
programming in FluR cells that renders them selectively vulnerable to the 
inhibition of: oxidative phosphorylation, and pyrimidine biosynthesis (Chapter IV). 
This study underscores the importance of selective metabolic dependence of 
highly anabolic (FluR cells, with a higher population in S phase) cells, and 
suggest that high pyrimidine biosynthesis, and glucose metabolism can be 
limiting in the cells with hyperactivated anabolic oncogenic pathways (such as 
mTORC1 in FluR cells). We show that targeting de novo pyrimidine biosynthesis 
pathway enzymes (by using PALA and leflunomide), or targeting associated 
mitochondrial respiration (by rotenone and antimycin) represent effective 
strategies to overcome Flu resistance. These data support the hypothesis that 
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targeting downstream functions of mTORC1 including, pyrimidine biosynthesis 
and glucose metabolism, in rapidly growing cells with deregulated mTORC1 
could be an important and effective means to bypass rapalog resistance.  On 
similar lines, a recent study reported that for cancer cells, which exhibit 
dysregulated mTORC1, serum lipids are an important source of unsaturated fatty 
acids under low O2 conditions (Young, Regina M et al.,Genes and Dev,  2013). 
Ours is the first report showing mTORC1 activation, as measured by p-
p70S6K (T389), and downstream p-CAD(S1859), as potential biomarkers of Flu-
resistance in leukemic cells. Our study provides the first evidence for the 
relevance of mTORC1-dependent activation of pCAD (S1859) in a disease 
setting. An important concern with targeting metabolic pathways could be the 
detrimental effects of such an approach on normal tissues. However, the success 
of antifolates, L-asparaginase, and other metabolic targets in cancers suggests 
that a therapeutic window can be successfully achieved for metabolic pathways 
(106). While PALA has been tested in clinical trials (135), leflunomide has been 
approved by FDA for rheumatologic diseases (136). In addition, although direct 
inhibitors of mitochondrial respiration, including uncouplers, could have obvious 
side-effects such as hypothermia. Metformin targets oxidative phosphorylation, 
and is one of the most readily prescribed drugs in the world (106).  Thus, 
targeting metabolism downstream of mTORC1 activation in cancers can make it 
to the clinic in the future. 
AIM II To investigate the role of autophagy in regulating cell death or 
resistance against Flu.  
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For cancer cells an undesirable consequence of their addiction to 
metabolic dysregulation is the accumulation of metabolic byproducts (e.g. ROS, 
aggregated proteins, and damaged organelles), and rapid exhaustion of cellular 
macromolecules(49). Autophagy functions as a prominent cellular recycling 
pathway. It allows removal of damaged proteins and organelles, and provides 
building blocks for enhanced biosynthesis, thereby acting as a prosurvival 
mechanism in this setting(49). Thus, autophagy could be a potential target in 
FluR cells under metabolic stress. However, autophagy is known to regulate 
variably, i.e. increase or decrease, the efficacy of chemotherapy(69). Therefore, 
another important question is to study the regulation of cell death by autophagy 
in a given context. 
 We studied the role and regulation of autophagy in two different settings 
— (i) drug inducible autophagy in Flu-sensitive cells and (ii) basal autophagy in 
FluR cells, and investigated the underlying mechanism of regulation of 
autophagy in these settings.  
In FluR cells metabolic stress activates AMPK-dependent, BECN1-
independent basal autophagy, which contributes to survival of these cells. Using 
genetic and pharmacologic inhibitors we show that FluR cells are addicted to 
constitutive autophagy for their survival (Chapter III). Increased expression of the 
glucose deprivation response network, including unfolded protein response, 
autophagy, glucagon signaling, and gluconeogenesis, genes,  has been 
described before in the context of acquired resistance to lapatinib in breast 
cancer cell lines (137). Similar to our findings in FluR cells, selective targeting of 
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autophagy associated with glucose-deprivation could overcome imatinib 
resistance (137). Thus, our findings are consistent with the prosurvival role of 
autophagy in aggressive forms of cancers (47, 115).  
In Flu-sensitive cells, Flu treatment leads to autophagy induction and 
increase in autophagic flux. Both pharmacological and genetic means of 
inhibition of autophagy, prevented Flu-mediated cell death supporting the 
prodeath role of autophagy in response to Flu (Chapter III). While protective 
function of autophagy in response to cellular stress is well accepted, the role of 
autophagy as a prodeath mechanism is controversial (45, 138). There have been 
several reports to show a tumor-suppressive role for autophagy (139). To cite a 
few examples, steroid sensitization of dexamethasome resistant cells by 
obatoclax is mediated by autophagic cell death (59). In addition, several 
oncogenes such as PI3K, AKT, mTOR, BCL-2 family are well established 
inhibitors of autophagy and tumor suppressors such as BECN1, PTEN, TSC1, 
TSC2, p53 and DAPK are known to activate autophagy (139). Infact, two 
transcriptional targets of p53 i.e. Sestrin2 (140) and DRAM (141) have been 
shown to induce autophagy mediated cell death. While autophagy has been 
described as an alternative form of cell death in the context of defective 
apoptosis (142), in our study we found that autophagy contributed to cell death in 
apoptosis competent Flu-sensitive cells. Thus, our data qualifies autophagy as 
more than a back-up mechanism in the context of Flu-induced cell death.  
Further, the antiapoptotic BCL-2 family proteins inhibit both apoptosis and 
autophagy, therefore, downregulation of antiapoptotic BCL-2 family proteins and 
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enhanced autophagy must coexist in cells dying in response to an apoptosis 
inducing therapeutic. However, in the drug-resistant cells that have an increased 
dependence on antiapoptotic proteins, whether autophagy is also inhibited 
remains unclear. One of the key findings in this report is that MCL-1 plays an 
essential role in regulating autophagy and cell death in both Fl-sensitive and Fl-R 
cells. Our data underscores the regulation of multiple cell death pathways by 
BCL-2 family proteins. FluR cells are a clear example of how important is the role 
of BCL-2 family in inhibiting cell death associated with autophagy, in addition to 
their anti-apoptotic role. Obatoclax, a pan-BCL-2 family small molecule inhibitor 
that binds the BH3 binding domain and inhibits a broad spectrum of anti-
apoptotic BCL-2 family proteins –effectively induced cell death in FluR cells, 
which have no Bim (apoptotic factor), further strengthens this concept. Clearly, 
obatoclax is killing FluR cells by releasing BECN-1 from its interaction with MCL-
1 and other BCL-2 family proteins. Free BECN-1 is then able to induce 
autophagy-associated cell death. A previous study in ALL cell lines and primary 
cells has shown the heterogeneous and cell type specific induction of a triple 
(apoptosis/autophagy/necroptosis) mechanism of cell death even within single 
cells by obatoclax (143). They clearly showed plasticity in obatoclax-induced cell 
death due to alternative pathway when either apoptosis or autophagy were 
inhibited (143). Cell death could be prevented only when both apoptosis and 
autophagy were inhibited together while disruption of either of them alone was 
ineffective in preventing cell death (143).  
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 Although Bcl-2 family has been implicated in the regulation of apoptosis in 
CLL and of autophagy in other systems (59, 144, 145), ours is the first report 
published that demonstrates the role of BCL-2 family in the regulation of 
autophagy, in addition to apoptosis, in CLL.  
These findings have important implication in designing novel therapeutic 
regimens for CLL patients. Although induction of autophagy may be a useful 
strategy to induce cell death in Flu-sensitive patients, these findings suggest that 
paradoxically, inhibition of autophagy may be a viable treatment strategy for CLL 
patients that have demonstrated Flu resistance. Finally from our data it is a 
tempting speculation that elevated basal autophagy, as that seen in FluR cells as 
well as their response to autophagy inhibition, may be used to predict patient 
response to autophagy inhibition. This warrants a more comprehensive analysis 
of basal autophagy levels and sensitivity to autophagy inhibition in CLL patients. 
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CHAPTER II 
Materials and Methods 
Reagents, and plasmids. Fludarabine (9-β- D -arabinofuranosyl-2-fluoroadenine 
5′-phosphate), chloroquine, 3-methyladenine and compound-C were purchased 
from Sigma Aldrich (St. Louis, MO). Everolimus from Selleck (Houston, TX), and 
rapamycin (Calbiochem, Billerica, MA). N-phosphonacetyl-L-aspartate (PALA, 
NSC224131) was acquired from the NCI/DTP Open Chemical Repository 
(http://dtp.cancer.gov) for a study in Dr. Christine McDonald’s laboratory 
(Cleveland Clinic). pLKO.1–puro control vector, shATG7 (cat no. SHCLNG-
NM_006395) and shLAMP2 (cat no. SHCLNG-NM_002294) Mission shRNAs 
from Sigma Aldrich (St. Louis, MO) and packaging plasmids pVSVG and dr 8.7 
from Invitrogen (Carlsbad,CA). Lentiviral infections were performed using 
polybrene (10 μg/ml) from Sigma Aldrich (St. Louis, MO), according to 
manufacturer’s instructions. Cells were treated with 10 μM Flu, 25 μM 
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chloroquine, 10 mM 3-methyladenine, 10 μM obatoclax (Selleck, Houston, TX) 
and 1 μM compound C, and 200 nM everolimus, unless otherwise stated. 
Cell lines and patient samples. Human pre-B acute lymphocytic leukemic 
Nalm-6, Reh, multiple myeloma RPMI-8226, histiocytic lymphoma U937, and 
acute T lymphocytic leukemic Molt-4 cell lines were obtained from the ATCC 
(Manassas, VA). Flu-resistant (FluR) cells were generated by initially culturing 
cells with a lower concentration (1 μM) of Flu for short periods of time followed by 
48 h of recovery time. The drug concentration was increased gradually until the 
desired resistance of twice the IC50 value was achieved. The resistant cells were 
intermittently treated with verapamil (Sigma Aldrich, St. Louis, MO) to eliminate 
the possibility of acquired resistance due to increased expression of efflux 
pumps. In addition to derivatized FluR cells, we used Mec-1 and Mec-2 cells (a 
gift from Dr. Y. Saunthararajah, Cleveland Clinic), which are CLL-derived cell 
lines known to be inherently resistant to Flu (146, 147). Cells were maintained in 
RPMI-1640 medium supplemented with 10% fetal bovine serum (Atlanta 
Biologicals, Lawrenceville, GA), L-glutamine (Gibco BRL, Gaithersburg, MD), and 
antibiotic-antimycotic (Invitrogen, Carlsbad, CA). Cell lines were verified 
periodically for morphological characteristics, growth rates, and response to 
stimuli using Annexin V/Propidium iodide staining or Trypan blue exclusion. 
Passage number was not allowed to exceed 15-20, and cell lines were routinely 
tested to be mycoplasma free. 
Peripheral blood samples were obtained from patients with CLL after 
patients gave informed consent according to protocols approved by the 
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Cleveland Clinic institutional review board, according to the Declaration of 
Helsinki. Briefly, lymphocytes from blood samples were purified by Ficoll-Paque 
PLUS (Amersham Biosciences, Piscataway, NJ) gradient centrifugation. Primary 
cells were cultured and cell death was assayed as previously described (148, 
149). 
Immunoblotting and immunoprecipitation. Cell lysates for immunoblotting and 
immunoprecipitation were prepared, as described previously.(150) The primary 
antibodies were used against: LC3, pAMPK (Thr172), AMPK, pULK1 (Ser467), 
ULK1, cleaved caspase-3, ATG7, p-p70S6K (T389), p70S6K, pCAD (S1859), 
cytochrome c, (Cell Signaling Technologies, Danvers, MA); MCL-1, BIM (BD-
Biosciences, San Jose, CA); NOXA (Enzo Life Sciences, Farmingdale, NY); p62 
(Fitzgerald Industries international, Acton, MA ); LAMP2, BCL-2, BCL-XL, 
BECN1, BAX (Santa Cruz Biotechnologies, Santa Cruz, CA); BAK (Calbiochem, 
Billerica, MA); β-actin (Sigma, St. Louis, MO); PUMA (Prosci Incorporated, 
Poway, CA); secondary anti-mouse HRP (Millipore, Danvers, Massachusetts); 
and secondary anti-rabbit HRP (Fisher Scientific, Pittsburg, PA). 
Confocal immunostaining. Treated cells were washed with PBS and cytoslides 
were prepared. The slides were then fixed with 2.0% paraformaldehyde/PBS for 
15 min at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 5 
min, blocked in 10% fetal bovine serum and 0.1% Triton X-100 in PBS for 1 h 
and incubated with the antibodies of interest diluted in blocking buffer for 1 h, 
followed by 1 h incubation with fluorescently conjugated secondary antibody, and 
finally with 4',6-diamidino-2-phenylindole (DAPI)  to stain nuclei. They were then 
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mounted in Vectashield (Vector Laboratories, Burlingame, CA). Images were 
collected using an HCX Plan Apo 63X/1.4N.A. oil immersion objective lens on a 
Leica TCS-SP2 confocal microscope (Leica Microsystems AG, Buffalo 
Grove, IL). The average LC3 puncta per cell was determined using Image J 
software. For LAMP2/LC3 colocalization, Pearson correlation coefficient was 
calculated using Image-Pro Plus software. For all image quantifications, data 
were collected from at least 30 cells. 
Cell viability and apoptosis assays.3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium inner salt(151) (MTS) 
assay (Promega, Madison, WI )  was used to assess cell proliferation. Data are 
expressed as % reduction in metabolic activity i.e. 100- ((O.D.490nm Untreated)–
(O.D.490nm Treated)] /(O.D.490nm Untreated)*100) versus the indicated 
concentrations of the drug. Cell death was measured by trypan blue staining.  
Apoptosis was measured using annexin V–fluorescein isothiocyanate and 
propidium iodide staining (BD Biosciences, San Jose, CA), as described 
previously.(152)  Cell death data were acquired on a BD FACS Calibur flow 
cytometer (BD Biosciences, San Jose, CA) and analyzed by CellQuest software.  
For clonogenic assay, 20 cells/ml were seeded using 30% FBS containing RPMI 
media in poly-lysine coated plates, and treated with desired treatments. After 8-
12 days, cells were stained with crystal violet and colonies were scored by an 
alpha image analyzer (Alpha Innotech Corp.). The % surviving fraction was then 
calculated according to the equation = (number of counts in treated 
sample/number of counts in NT sample) × 100. (PMID:18060882). The 
63 
 
interaction between PALA and Flu in clonogenic assays was determined using 
isobolographic method of Chou and Talalay, (PMID:6382953). The combination 
index was calculated using Compusyn software (www.combosyn.com), 
combination index<1 indicates synergism, fraction affected = (100-%surviving 
fraction)/100.  
Extracellular flux (XF) analysis. A Seahorse Bioscience XF-24 Flux Analyzer 
was used to measure the OCR and ECAR (Seahorse Bioscience, North Billerica, 
MA). Cell density titrations were first performed to define the optimal seeding 
density for Nalm-6 and Nalm-6-FluR cells. Suspension cells were seeded in 
Seahorse Cell-Tak-coated XF 24-well cell culture microplates in 150 μL 
Seahorse assay medium [unbuffered DMEM (Sigma D5030), supplemented with 
2 mM glutamine, 1mM pyruvate and 11mM glucose] pre-warmed to 37°C. In the 
subsequent experiments, Nalm-6 and Nalm-6-FluR cells were seeded in growth 
media in plates as described above with 95,000 Nalm-6 cells or 50,000 Nalm-6-
FluR cells per well to ensure about 90% surface coverage at the time of the 
experiment. The cells were incubated for 30 min at 37°C to allow media 
temperature and pH to reach equilibrium. During this time, selective metabolic 
inhibitors were pre-loaded into injection ports of the cartridge to achieve final 
concentrations of 2-DG (100 mM), FCCP (1.5 μM), oligomycin (1.5 μM), rotenone 
(0.75 μM), and antimycin A (0.75 μM). Oligomycin and FCCP titrations were 
performed for each cell line. Before the first rate measurement, total volume was 
adjusted to 500 μL for mito-stress using the Seahorse media and incubated for 
an additional 15 min. At the end of incubation, the plate was placed in the 
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Seahorse XF24 analyzer. During the assay, baseline rates were measured 3 
times. OCR was reported in nmol/min and ECAR in milli-pH (mpH)/min and 
further normalized per each cell type. Substrates and selective inhibitors were 
injected during the measurements and mixed for 3 to 5 min. OCR and ECAR 
were then measured 3 times each.  
Cytochrome c release. Cells were washed in 1 x PBS and resuspended in the 
lysis buffer (20 mM Hepes, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM 
EGTA, 1 mM dithiothreitol, and 250 mM sucrose). To ensure complete cell lysis, 
cells were drawn into a 28 1/2 or 30 1/2 -gauge needle using a syringe and then 
expelled a minimum of 20 times. Unbroken cells were removed by spinning at 
5,000 rpm for 5 min. The supernatant was again centrifuged at 14,000 rpm for 30 
min at 4˚C to separate the mitochondrial fraction (pellet) from the cytoplasm 
(supernatant). Protein was quantified using Bradford’s method, 5 × SDS sample 
buffer was added to the supernatants, and analyzed on 15% SDS-PAGE gels to 
probe for cytochrome c release. 
ATP quantification. The quantity of ATP was measured using the Mitochondrial 
ToxGlo luminescent cell viability assay (Promega, Madison, WI) according to the 
manufacturer’s protocol. Briefly, cells were seeded in white 96-well microplates at 
1.0 × 104 cells per well in 100 μL growth media, and treated as indicated in 
Figure 3 for 2 h at 37ºC, 5% CO2. Then, 100 μL luminogenic ATP detection 
reagent was added and luminescence intensity from each well was measured 
using a multi-label plate reader (Wallac Victor 1420; Perkin Elmer, Waltham, 
MA).  
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siRNA transfection. Transfections were performed with control-GFP or S6K1 
siRNAQiagen (Valencia, CA, USA) using the Amaxa Nucleofector Kit V (Lonza) 
according to the manufacturer's protocol. In brief, (3.0 × 106) cells were 
transfected with 500 nM siRNA using program D023. 
Statistical analysis. Statistical comparisons between two groups were 
conducted by using the Student’s t test and between multiple groups using 2-way 
ANOVA with the Prism software (version 5.01). Error bars indicate s.d., which 
was calculated from three independent experiments performed in triplicates.  
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CHAPTER III 
BECN1 and BIM interaction with MCL-1 determine FluDARABINE-resistance 
in leukemic B cells 
3.1 Introduction 
Fludarabine (Flu) is a purine nucleoside analog that is incorporated into 
the DNA and which inhibits DNA/ RNA synthesis and DNA repair. Therefore, 
apoptosis ultimately occurs in both proliferating and quiescent cells (125). Flu is 
an essential component of therapy for chronic lymphocytic leukemia (CLL) (124). 
Although Flu-based regimens have been successful in improving the overall 
outcome in CLL patients, primary or acquired resistance limits the effectiveness 
of this therapy (124). Unfortunately, Flu-refractory patients are resistant to most 
other chemotherapies. Thus, a mechanistic understanding of such resistance at 
the molecular level is urgently needed for the rational development of appropriate 
alternative or combination therapies in the clinic.  
 The BCL-2 family proteins that regulate apoptotic cell death mediate 
chemoresistance in various cancers,(153) including CLL (149, 150, 154). The 
anti-apoptotic members of this family, such as BCL-2, BCL-xL, MCL-1, BCL-W, 
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and BFL-1 inhibit apoptosis by binding and inhibiting pro-apoptotic BCL-2 family 
proteins (155). The pro-apoptotic members include “effector” and “BH3-only” 
proteins which, in turn, include “direct activators” and “sensitizers”. Upon 
activation the “effector” proteins BAX and BAK oligomerize and form pores on the 
outer membrane of mitochondria to release cytochrome c and subsequently lead 
to caspase activation and apoptotic cell death (156, 157). Activation of “effector” 
proteins requires interaction with the “direct activators”, BIM and BID.  
“Sensitizers”, such as PUMA, NOXA, BAD, BIK, BMF interact with and prevent 
anti-apoptotic proteins from interacting with BIM and BID (158). 
 The functionally diverse BCL-2 family proteins,(159) in addition to 
inhibition of apoptosis, are known to block autophagy,(54, 160) a catabolic 
process regulating cellular turnover in both normal as well as cancer cells. A 
double membrane vesicle called an autophagosome initially forms around the 
target substrate and later fuses with lysosomes to form autolysosomes, where 
degradation takes place.(39, 161) The nucleation of the autophagosomal 
membrane is regulated by beclin1 (BECN1, also known as ATG6), a BH3-
domain containing protein, which forms a class III phosphatidylinositol-3 kinase, 
PI3K core-complex consisting of BECN1/Vps34/Vps15 and recruits essential 
autophagic proteins to a pre-autophagosomal membrane.(54, 161)The anti-
apoptotic BCL-2 family proteins, including BCL-2, BCL-xL, and MCL-1 block 
autophagy by direct interaction and inhibition of BECN1.(59, 160, 162) 
 As autophagy can cause both cell death and survival,(163-165) in the 
present study, we investigated the molecular alterations of autophagy and BCL-2 
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family proteins in response to acquired chemoresistance. By comparing Flu-
sensitive cells and –resistant (FluR) cells that were generated by chronic 
exposure to Flu, we delineate how the resistant tumor cells adapt to 
chemotherapy by their ability to evade apoptosis by activating autophagy. 
Targeting alternative cell survival or cell death pathways could provide attractive 
treatment strategies.  
3.2 Results 
3.2.1 Fludarabine induces autophagy and enhances autophagic flux.  
To study the regulation of Flu-induced cell death or acquired resistance by 
autophagy, we first examined Flu-induced autophagy in Flu-sensitive cells using 
LC3 (also known as ATG8) processing as a marker of autophagy.As there are no 
Flu- sensitive CLL cell lines available, we chose pre B leukemic cell lines as a 
Flu-sensitive model (IC50 values of ~10 μM), as reported in a previous study to 
investigate the autophagic pathway(166). During autophagy, the 18-kDa cytosolic 
LC3I is conjugated to phosphatidylethanolamine to form the 16-kDa LC3II, which 
associates with the autophagosomal membrane.(161, 167) Flu treatment 
increased LC3-II levels, as determined by immunoblotting, in both Nalm-6 and 
Reh cells (Figure 3.1a). Consistently, immunostaining analysis for LC3 in Nalm-6 
cells treated with Flu for 1 h showed an increase in the number of LC3 puncta, 
indicating an enhanced autophagosome formation, p<0.05 (Figure 3.1b and c) 
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Figure 3.1 Fludarabine induces autophagy and enhances autophagic outflux.(a) 
Western blot for LC-3 I/II expression, with β-actin serving as a loading control, in 
Nalm-6 and Reh cells treated with Fludarabine (Flu) for the indicated time. (b) 
Representative images of LC3 stained cytospins of Nalm-6 cells treated with Flu 
for 1 h.  Nuclei were stained with DAPI. Image quantification of LC3 puncta is 
shown in (c).(d)Western blot for LC-3 I/II, p62/SQSTM1(p62), and β-actin as a 
loading control in Nalm-6 and Reh cells pretreated with chloroquine (CQ) for 1 h 
followed by 4 h treatment with Flu. (e) Confocal immunostaing for LC3I/II in 
Nalm-6 cells pretreated with CQ for 1 h followed by 4 h treatment with Flu. Nuclei 
were stained with DAPI.Quantification of LC3 puncta staining is shown in (f); 
*p<0.05, n=3. 
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Next, the autophagic flux was examined to distinguish between regulation of 
synthesis vs. degradation of LC3I/II (161).  To determine autophagic flux due to 
Flu, chloroquine (CQ) was used to inhibit degradation through autophagy by 
blocking lysosomal acidification (161). CQ pretreatment followed by 4 h Flu 
treatment enhanced LC3 processing in both Nalm-6 and Reh (Figure 3.1d), as 
well as LC3 puncta in Nalm-6 cells, p<0.05 (Figure 3.1e and f).  Additionally, the 
levels of p62/SQSTM1 that is degraded by autophagy,(161, 168) decreased after 
Flu treatment. Importantly, CQ pretreatment rescued Flu-induced p62/SQSTM1 
degradation (Figure 3.1d). Thus, Flu induces autophagy and enhances 
autophagic flux in leukemic B cell lines. 
3.2.2 Inhibition of autophagy prevents Fludarabine-induced cell death. 
 Next, we used genetic and pharmacological approaches to inhibit autophagy to 
investigate whether autophagy modulated cellular response to Flu treatment. 
Short-hairpin (sh) RNA- mediated knockdown of LAMP2, an essential lysosomal 
protein required for the late stages of autophagy, i.e. autophagosome to 
lysosome fusion(161, 169) prevented basal p62/SQSTM1 degradation in both 
Nalm-6 and Reh cells compared to their respective shControl-expressing cells 
(Figure 3.2c).  
Moreover, Flu-induced cell death was significantly reduced in both shLAMP2-
expressing Nalm-6 (p<0.001) and Reh (p<0.01) cells compared to their 
respective shControl-expressing cells (Figure 3.2a). Similarly, in Nalm-6 cells 
expressing shRNA against ATG7 (Figure 3.2d), an essential autophagy protein 
that is required for LC3 processing (161, 170), cell death in response to Flu 
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decreased significantly (p<0.05) (Figure 3.2b),  Likewise, pharmacological 
inhibition of autophagy by 3-methyladenine (3-MA), known to inhibit the class III 
PI3K complex required for nucleation of autophagosomes,(161) also significantly 
prevented Flu-induced cell death in Nalm-6 cells (p<0.05)  (Figure 3.2e). 
Together, these findings suggest that autophagy-associated cell death occurs in 
response to Flu treatment in Nalm-6 and Reh cells. 
3.2.3 Developing Fludarabine resistance after chronic exposure. 
 To determine how Flu resistance impacts on the therapeutic response of 
leukemic cells, we derived Flu-resistant (FluR) cells. The Nalm-6- and Reh-FluR 
cells showed no growth reduction, in contrast to a significant dose-dependent 
decrease observed in Nalm-6 (p<0.0001) and Reh (p<0.01) cells, respectively, 
following 24 h of Flu treatment (Figure 3.3a). Trypan blue staining showed ~ 50% 
cell death in both Nalm-6 (p<0.0001) and Reh (p<0.001) cells compared to <5% 
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Figure 3.2 Inhibition of autophagy prevents Fludarabine-induced cell death.(a) 
Cell death analysis in shControl and shLamp2-expressing cells in response to 24 
h Fludarabine (Flu) treatment as determined by trypan blue staining. (b) Cell 
death analysis in shControl and shATG7-expressing cells in response to 24 h Flu 
treatment as determined by Annexin V/ PI staining. (c)Immunoblotting for levels 
of LAMP2, p62, and β-actin in Nalm-6 and Reh cells expressing shControl or 
shLAMP2 lentiviral vectors. (d)Immunoblotting for levels of ATG7, p62, and β-
actin in Nalm-6 cells expressing shControl or shATG7.(e) Nalm-6 cells were 
pretreated with 3-methylalanine (3-MA) for 1 h followed by 24 h Flu treatment 
and cell death was determined by Annexin V/ PI staining. All data are expressed 
as mean ± s.d. of percentage of cell death; *p<0.05, **p<0.01, ***p<0.001, n=3. 
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in the respective FluR cells following 24 h treatment with Flu (Figure 3.3b). 
Similarly, AnnexinV/PI-staining showed ~40-50% increase in cell death in Nalm-
6, but not in the derivative FluR cells with 24 h Flu treatment (p<0.001) (Figure 
3.3c). Interestingly, the FluR cells were resistant specifically against Flu. In 
contrast, bendamustine, a bifunctional purine analog and alkylating agent 
approved by FDA for CLL treatment(124) led to even higher induction of cleaved 
caspase-3  (Figure 3.3d) and higher dose dependent increase in growth 
reduction (Figure 3.3e) in FluR compared to Nalm-6 cells.  
3.2.4 Fludarabine-resistant cells are addicted to basal autophagy.  
Next, we compared the levels of autophagy between Flu sensitive and 
resistant cells. As found previously, Flu treatment caused an induction of LC3 II 
in both Nalm-6 (Figure 3.4a, top) and Reh cells (Figure 3.4a, bottom). However, 
in both Nalm-6 and Reh FluR cells, there were higher LC3 II levels in the 
untreated cells than in the respective parental cells (Figure 3.4a, top, Figure 3.4a, 
bottom), suggesting a higher constitutive autophagy, which did not increase 
further with Flu treatment.  
 To further investigate whether the increase in LC3 II levels in FluR cells 
was due to higher basal autophagy or inhibition of flux,(161) we compared the 
autophagosome-lysosome fusion between Nalm-6- and Nalm-6-FluR cells 
treated with Flu in the presence or absence of CQ, using confocal microscopy. 
As demonstrated by co-localization of LC3, a marker for autophagosomes, and 
LAMP2, a marker for lysosomes (Figure 3.4b, 3.4c), CQ treatment alone in Nalm-
6 cells caused an increased number of LC3 puncta,  
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Figure 3.3 Developing Fludarabine resistance after chronic exposure.(a) Dose 
reponse for the effect of 24 h Fludarabine (Flu) treatment on cell growth in Nalm-
6, Nalm-6 FluR, Reh, and Reh FluR cells, as determined by the MTS assay. 
(b)Cell death analysis in the indicated cell lines in response to 24 h Flu treatment 
as determined by trypan blue staining. (c) Cell death analysis in Nalm-6 and 
Nalm-6 FluR cells in response to 24 h Flu treatment as determined by Annexin V/ 
PI staining. All data are expressed as mean ± s.d. of percentage of cell death 
from three independent experiments.(d) Western blot analysis for the levels of 
cleaved-caspase-3, as well as β-actin as a loading control, in Nalm-6 and Nalm-
6-FluR cells treated with the indicated concentrations of bendamustine or Flu for 
6 h. (e) Dose reponse for the effect of 24 h bendamustime (Bd) treatment on cell 
growth in Nalm-6 and Nalm-6 FluR cells, as determined by the MTS assay. 
; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, n=3.  
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which co-localized with LAMP2 puncta (p<0.0001). Therefore, CQ inhibited 
autophagic degradation or flux through lysosomes. Additionally, Flu-treatment 
alone of Nalm-6 showed a significant increase in LC3 puncta staining as well as 
LAMP2 co-localization compared to untreated Nalm-6 cells (p<0.0001). 
Moreover, Flu treatment following CQ pretreatment of Nalm-6 cells greatly 
enhanced both LC3 puncta staining as well as co-localization with LAMP2 
(p<0.0001), clearly indicating induction as well completion of autophagy. In 
untreated FluR cells, there were LC3 puncta, which co-localized with LAMP2 to a 
greater extent than in Nalm-6 cells (p<0.001), which were further increased by 
CQ treatment (p<0.001), suggesting basal autophagy induction as well ongoing 
flux in FluR cells.  
 Next, we determined the effect of inhibition of autophagy in FluR cells by 
depleting cells of LAMP2 using shRNA. LAMP2 expression was significantly 
reduced in shLAMP2- compared to that in shControl-expressing FluR cells 
(Figure 3.4d). Moreover, cell death was significantly increased (p<0.05) in 
shLAMP2-expressing compared to shControl-expressing FluR cells (Figure 
3.4e). In addition, inhibition of autophagy by shLAMP2 sensitized FluR cells to 
Flu. Similar findings were obtained upon pharmacological inhibition of autophagy 
using CQ in FluR cells (Figure 3.4f). These findings were validated in the CLL  
derived cell lines Mec-1 and Mec-2. Consistent with previous studies (146, 147), 
both of these cell lines were resistant to Flu  as no significant decrease in growth  
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Figure 3.4 Fludarabine-resistant cells are addicted to basal 
autophagy.(a)Western blot analysis for the levels of LC-3 I/II and β-actin used as 
a loading control, in Nalm-6 and Nalm-6 FluR (top) Reh and RehFluR cells 
(bottom) in response to Fludarabine (Flu)-treatment for the indicated times. 
(b)Nalm-6 and Nalm-6 FluR cells were pre-treated with CQ for 1 h +/- Flu (4 h).  
Cells were then fixed, stained with an antibody against LC3 and LAMP2 along 
with nuclear staining by DAPI and analyzed by immunofluorescence. (c) 
Correlation index for LC3 and Lamp2 in the indicated samples. (d)Cell death 
analysis in ShControl and shLamp2-expressing Nalm-6-FluR cells in response to 
24 h Flu treatment, as determined by trypan blue staining.(e) Western blot 
analysis for the levels of LAMP2 as well as β-actin in Nalm-6-FluR cells 
expressing shControl or shLAMP2. (f) Nalm-6 FluR cells were pretreated with CQ 
for 1 h followed by 24 h Flu treatment and cell death was determined by Annexin 
V/ PI staining. (g) Dose reponse for the effect of 24 h Flu treatment on cell growth 
in Mec-2 cells, as determined by the MTS assay. (h) Dose reponse for the effect 
of 24 h fludarabine (Fd) treatment on cell growth in Mec-1 and Mec-2 cells, as 
determined by the MTS assay. (i) Mec-2 cells were pretreated with CQ for 1 h 
followed by 24 h Flu treatment and cell death was determined by Annexin V/ PI 
staining. (j) Dose reponse for the effect of 24 h CQ treatment on cell growth in 
Mec-1 and Mec-2 cells, as determined by the MTS assay. All data are expressed 
as mean ± s.d. of percentage of cell death from three independent experiments; 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, n=3. 
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reduction was observed even after treatment with up to 100 µM Flu for 24 h, with 
Mec-1 being more resistant (Figure 3.4g and 3.4h). Importantly, CQ pretreatment 
sensitized Mec-2 cells towards Flu-induced cell death (p<0.05) (Figure 3.4i). CQ 
treatment alone induced cell death in Mec-2 cells (Figure 3.4i) and all of the Flu-
resistant cell lines we tested. These findings further support that these cells are 
addicted to basal autophagy. Interestingly, Mec-1 were more sensitive to CQ 
treatment than Mec-2 (Figure 3.4j). This suggests that Mec-1 are more addicted 
to constitutive autophagy than Mec-2 cells, the latter also being relatively less 
resistant to Flu. Thus, FluR cells become addicted to higher constitutive 
autophagy and inhibition of autophagy in FluR cells sensitizes them to Flu 
treatment. 
3.2.5 Sustained MCL-1 inhibits BECN1-dependent autophagic cell death in 
FluR cells.  
To distinguish between the opposing roles of autophagy in regulating cell 
death, i.e. being pro-death in Flu-sensitive and pro-survival in FluR cells, we next 
investigated the relationship between autophagy and apoptosis at the molecular 
level. One of the best studied complexes where components of both autophagy 
and apoptosis have been known to converge is the multimeric class III PI3K, 
BECN1/Vps34/Vps15-complex (59, 160, 162). We first examined the levels of 
various BCL-2 family proteins and BECN1 in Flu-treated Nalm-6 and Reh cells 
and their resistant derivatives. In both Nalm-6 and Reh cells we observed 
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Figure 3.5 Sustained MCL-1 inhibits BECN1-dependent autophagic cell death in 
FluR cells. (a)Nalm-6 and Nalm-6 FluR as well as (b) Reh and Reh FluR cells 
were treated with Flu (Flu) for the indicated time and 4 h, respectively. Cell 
lysates were analyzed by Western blotting for the indicated proteins. β-actin was 
used as a loading control. Nalm-6 and Nalm-6 FluR cells were treated with Flu 
for 24 h, and (c) MCL-1 immunoprecipitates were analyzed for the presence of 
proteins with the corresponding primary antibodies. (d)BCL-2 immunoprecipitates 
were analyzed for the presence of proteins with the corresponding primary 
antibodies. (e)BCL-xL immunoprecipitates were analyzed for the presence of 
proteins with the corresponding primary antibodies. (f) Cell death analysis in 
siControl and siBIM-expressing Nalm-6 cells in response to 24 h Flu (Flu) 
treatment as determined by trypan blue staining. (g) Immunoblot analysis of BIM 
and β-actin as a loading control in Nalm-6 cells expressing siControl or siBIM. (h) 
Nalm-6 and Nalm-6 FluR cells were treated with obatoclax for 24 h, and MCL-1 
immunoprecipitates were analyzed for the presence of the indicated proteins. 
(i)Nalm-6 and Nalm-6 FluR cells were treated with increasing concentrations of 
obatoclax (ob) for 24 h and the effect on cell viability was assessed by the MTS 
assay.(j) CLL cells were treated with Flu +/- obatoclax (5 µM) for 48 h and cell 
death was determined by Annexin V/ PI staining; n=6, *p<0.05, **p<0.01, 
***p<0.001 .  
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downregulation of MCL-1 within 4 h of Flu treatment. In contrast, MCL-1 levels 
were maintained in the resistant derivatives following Flu treatment (Figure 3.5a 
and b). Interestingly, BIM levels were greatly reduced and BCL-xL levels were 
increased in FluR compared to Flu-sensitive cells. Expression of the other BCL-
2-family proteins examined was largely unaffected.  
 Next, we immunoprecipitated MCL-1 from both Nalm-6 and FluR cells 
treated with Flu, and examined the levels of associated BECN1 and BIM. In 
untreated Nalm-6 cells, both BECN1 and BIM were bound to MCL-1 (Figure 
3.5c). Following Flu treatment in Nalm-6 cells there was no BECN-1/MCL-1 
complex, as expected due to degradation of MCL-1 following Flu treatment in 
these cells. Thus, BECN-1 dissociated and led to the induction of autophagy. 
Interestingly, there was much more MCL-1 bound to BECN1 in FluR as 
compared to Nalm-6 cells suggesting an inhibition of BECN1-mediated 
autophagy in FluR cells. In addition, BIM was released from the MCL-1 complex 
following Flu treatment in Nalm-6 cells, therefore, was capable of initiating 
apoptosis. Consistent with the very low levels of BIM in FluR cells (Figure 3.5b), 
we did not find any BIM in complex with MCL-1 (Figure 3.5c).  
Moreover, Flu-induced cell death was significantly reduced in siBIM-
expressing compared to siControl-expressing Nalm-6 (p<0.05) cells (Figure 3.5f 
and 3.5g). Additionally, we also examined BECN1 and BIM interactions with 
BCL-2 and BCL-xL in Nalm-6 and FluR cells treated with Flu (Figure 3.5d and 
3.5e). In Nalm-6 cells, none of these interactions changed following Flu treatment 
compared to untreated cells. In contrast, in FluR cells, there was enhanced 
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interaction of BECN1 with both BCL-2 and BCL-xL compared to that in Nalm-6 
cells. These results suggest that BCL-2 family proteins promote cell survival by 
inhibition of both apoptosis as well as BECN1-mediated autophagy in FluR cells.  
 Consistently, treatment with obatoclax, a small-molecule antagonist of the 
BH3-binding domain of BCL-2 proteins,caused release of both BIM and BECN1 
in Flu-sensitive cells and BECN1 in FluR cells from the MCL-1 complex(Figure 
3.5h). Importantly, Nalm-6- and Nalm-6-FluR cells were both sensitive to 
obatoclax, validating the importance of functional BCL-2 family proteins in FluR 
cells (Figure 3.5i). Moreover, in primary CLL cells 24 h obatoclax treatment 
significantly increased (p<0.01) the Annexin V/PI-positive cell population (Figure 
3.5j), regardless of Flu sensitivity.  
Thus, degradation of MCL-1 following Flu treatment in Flu-sensitive cells 
released BECN1 and BIM from the MCL-1 complex and, therefore, autophagy 
and apoptosis occurred simultaneously. In contrast in FluR cells, low BIM levels 
prevented apoptosis. In addition, BCL-2, BCL-xL, and undegraded MCL-1 kept 
BECN1 sequestered and prevented activation of autophagy associated with cell 
death. Importantly, inhibition of BCL-2 family using obatoclax could target both 
Flu-sensitive cells by induction of BIM-dependent apoptosis and BECN1 
dependent autophagy and FluR cells by induction of BECN1 dependent 
autophagy. 
3.2.6 Basal autophagy in FluR cells is dependent on AMPK but not BECN1. 
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Figure 3.6 Basal autophagy in FluR cells is dependent on AMPK but not 
BECN1.(a)Immunoblot analysis of LC3, BECN1, p62, and β-actin as a loading 
control in Nalm-6 and Nalm-6 FluR cells expressing siControl or siBECN1 treated 
with Fludarabine (Flu) for 4 h. (b) a) Cell death analysis in siControl and 
siBECN1-expressing cells in response to 24 h Flu (Flu) treatment as determined 
by trypan blue staining. (c) Immunoblot analysis of p62 and β-actin as a loading 
control in Nalm-6 FluR cells expressing siControl or siBECN1 treated with 
obatoclax for 24 h. (d) Cell death analysis in Nalm-6 and FluR Cells in response 
to serum starvation for the indicated time, as determined by trypan blue staining, 
****p<0.0001, n=3. (e) Nalm-6 and Nalm-6 FluR were treated with Flu (Flu) for 
the indicated time. Cell lysates were analyzed by Western blotting for pAMPK-
Thr172, AMPK, pULK-1-Ser467, and ULK-1. (f) Nalm-6 and Nalm-6 FluR, and (g) 
Reh cells were treated with Comp C +/- Flu and comp C, respectively, for the 
indicated time and analyzed by Western blotting for the levels of pAMPK-Thr172, 
AMPK, pULK-1-Ser467, and ULK-1. 
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To reconcile our findings of that cell death associated but not basal 
autophagy was inhibited in FluR cells, with reports of BECN1-independent 
autophagy,(41) we next asked whether basal autophagy  
in FluR cells was independent of BECN1. We investigated whether depletion of 
BECN1 using siRNA approach affected basal and/ or inducible autophagy in 
Nalm-6  and FluR cells. Immunoblot analysis indicated a significant reduction in 
BECN1 levels in siBECN1-expressing cells compared to siControl-expressing 
Nalm-6 and FluR cells (Figure 3.6a). In siBECN1-expressing Nalm-6 cells LC3 
processing by Flu treatment was decreased compared to their respective 
siControl-expressing cells (Figure 3.6a), 
 In addition, the levels of p62/SQSTM1 were higher in both untreated and 
Flu-treated Nalm-6 cells suggesting that basal as well as Flu-induced autophagy 
is BECN1 dependent in Nalm-6 cells. However, in FluR cells, there was no 
change in LC3 processing nor p62/SQSTM1 levels in FluR cells depleted of 
BECN1 (Figure 3.6a), further supporting BECN1-independent basal autophagy in 
FluR cells.  
Further, Flu-induced cell death was significantly reduced in siBECN1-
expressing Nalm-6 cells (p<0.001) compared to siControl-expressing cells 
(Figure 3.6b). This was expected, consistent with what we have shown earlier 
(Figure 3.2), Flu induces BECN1 dependent autophagy-associated cell death in 
Nalm-6 cells. Interestingly, in FluR cells presence or absence of BECN1 made no 
difference to cell survival in response to Flu (Figure 3.6b). These findings further 
substantiate that basal autophagy in FluR cells is BECN1 independent, such that 
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inhibition of autophagy by LAMP-2 knockdown in these cells causes cell death 
(Figure 3.4e) whereas BECN-1 knockdown had no effect on cell viability. 
Importantly, obatoclax-induced autophagy was reduced in siBECN1-FluR 
compared to that in siControl-FluR cells, as determined by p62/SQSTM1 levels 
by Western blotting, supporting the fact that obatoclax relieves MCL-1-mediated 
inhibition on BECN1 in FluR cells, thus leading to BECN1 dependent autophagy 
(Figure 3.6c). 
 Under energy stress conditions, the AMP-activated protein kinase 
(AMPK) activation has been reported to activate autophagy by direct 
phosphorylation of Unc51-like kinase (ULK-1), which forms a multimolecular 
complex associated with initiation of autophagy (24). Interestingly, FluR cells 
showed increased sensitivity to serum starvation (Figure 3.6d)  and higher basal 
AMPK and ULK-1 activation and compared to Nalm-6 cells (Figure 3.6e) 
suggesting higher metabolic stress in FluR cells. In addition, Flu treatment 
caused AMPK and ULK-1 activation in Nalm-6 and Reh cells as determined by 
Western blot analysis of pAMPK and pULK-1 (Figure 3.6e and 3.6f), suggesting 
that Flu-induced autophagy is mediated by AMPK. Importantly, inhibition of 
AMPK in Nalm-6, Reh and FluR cells using compound C (Comp C) inhibited 
autophagy, as determined by pULK-1 levels (Figure 3.6 f and 3.6g).   
Thus, Flu-induced autophagy was AMPK- and BECN1-dependent in Flu-
sensitive cells. However, basal autophagy in FluR cells, to which they were 
addicted as a result of increased metabolic demand, was independent of BECN1 
but dependent on AMPK. Taken together, these data establish that autophagy is  
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Figure 3.7 Model for acquired Fludarabine-resistance mechanism.MCL-1 
degradation following Fludarabine (Flu) treatment released BIM and BECN1, 
leading to apoptosis and cell death-associated autophagy in Flu-sensitive cells. 
In FluR cells there was low BIM expression and BECN1 was inhibited by high 
MCL-1/BECN1 interaction. FluR cells have a higher metabolic demand, which 
activates AMPK-dependent autophagy and promotes survival in these cells. 
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critical for regulating cell death and resistance to Flu. Inhibition of BECN1-
dependent autophagy, reduced  levels of BIM and AMPK-dependent basal 
autophagy are key determinants of acquired resistance against Flu (Figure 3.7). 
3.3 Discussion 
 Here we show that autophagy is a critical regulator of cellular response to 
Flu in leukemic B cells. Additionally, we show for the first time that Flu-induced 
autophagy is BECN1-dependent and is associated with cell death in Flu-sensitive 
cells. Autophagy represents an important regulatory mechanism of cellular 
response to adverse stimuli. While the protective function of autophagy in 
response to cellular stress is well accepted, the role of autophagy as a prodeath 
mechanism is controversial.(138, 171)Our data suggest that autophagy 
differentially regulates Flu-induced cell death in sensitive cells and those with 
acquired Flu resistance. Thus, Flu induces autophagy as well as enhances 
autophagic flux in Flu-sensitive leukemic B cells, as previously reported in CLL 
cells (172). In Flu-sensitive cells, autophagy contributes to cell death in response 
to Flu. Both pharmacological inhibition by 3-MA as well as shRNA-mediated 
knockdown of LAMP2 and ATG7 genes that are essential for autophagy 
prevented Flu-mediated cell death.  
 Based on our data on the pro-death function of autophagy in Flu-sensitive 
cells, we expected a complete inhibition of autophagy in FluR cells.Surprisingly, 
FluR cells showed markers of increased constitutive autophagy: higher LC3 II 
expression, LC3 puncta formation, and fusion between autophagosomes and 
lysosomes. Additionally, we found that the higher basal autophagy was essential 
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for the survival of FluR cells, including the CLL cell lines Mec-1 and Mec-2, as 
cell death increased upon autophagy inhibition. These findings indicate that other 
adaptive changes might have happened during the chronic exposure to Flu 
during selection for Flu resistance, which contributed to overcome cell death 
despite increased autophagy. 
 Importantly, in Flu-sensitive cells MCL-1 degradation following Flu-
treatment released BECN1 from the MCL-1 complex to cause autophagy-
associated cell death. In contrast in FluR cells, MCL-1 levels were sustained, 
leading to sequestration of BECN1 and inhibition of BECN1-mediated autophagy 
(173). Although the BCL-2 family has been implicated in the regulation of 
apoptosis and Flu resistance in CLL, and of autophagy in other systems,(59, 144, 
174) to our knowledge this is the first report that demonstrates the role of BCL-2 
family in the regulation of autophagy, in addition to apoptosis, in response to Flu, 
a prototypical nucleoside analog and DNA damage-inducing therapeutic agent.  
 The current literature suggests that BCL-2 family members, especially 
MCL-1, play an important role in regulating in vitro drug resistance in CLL.(154, 
175) Importantly, the BIM-MCL-1 complex has been shown to be critical for 
apoptosis modulation in CLL (176). Here, we show that endogenous MCL-1 
sequestered BIM in untreated Flu-sensitive cells to inhibit apoptosis. Flu 
treatment reduced MCL-1 levels and thus released BIM to initiate apoptosis. 
Interestingly, FluR cells had remarkably low BIM levels, which atleast, in part, 
were regulated transcriptionally (data not shown). Thus, we show for the first time 
that levels of BIM and its interaction with MCL-1 are important determinants of 
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Flu-mediated apoptosis. Indeed, we found that the pan-Bcl-2 inhibitor obatoclax 
potently induced cell death in both Flu-sensitive and FluR cell lines as well as in 
PBMCs isolated from CLL patients, as shown previously(177). 
Importantly,obatoclax treatment induced BIM and BECN1 release from the MCL-
1 complexes in Flu-sensitive and BECN1 release from MCL-1 in FluR cells in 
further support of our interpretation that MCL-1 regulates both apoptosis and cell 
death associated with autophagy in response to Flu. 
We found that FluR cells exhibit increased sensitivity to serum starvation 
compared to Flu-sensitive cells.The increase in metabolic demand may, in part, 
explain the increased dependence of FluR cells to basal autophagy. Our data 
suggest that basal autophagy in FluR cells, but not in Flu-sensitive cells, was 
independent of BECN1. Consistently, we found that siBECN1-expressing Flu-
sensitive cells showed reduced autophagic outflux in the presence of Flu, 
whereas siBECN1-expressing FluR cells did not show inhibition of basal 
autophagy.  
 Previous studies have suggested that activation of AMPK, a sensor of the 
cellular energy status, stimulates autophagy via AMPK-mediated phosphorylation 
of ULK1.(24)Consistent with these findings, we found that AMPK was activated in 
response to Flutreatment in Flu-sensitive cells and that AMPK activation was 
remarkably higher in FluR compared to Flu-sensitive cells. In addition strong 
activation of AMPK corresponded to phosphorylation of ULK-1on Ser467, one of 
the AMPK target sites on ULK-1 asreported (24). Moreover, inhibition of AMPK 
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prevented ULK-1 activation. Thus, these results suggest that AMPK plays a 
critical role in Flu-mediated autophagy. 
Flu resistance is often associated with loss of p53.(178) We found that 
both Flu and ionizing radiation (IR), a prototypical DNA damaging reagent (152). 
induced p53 in Flu sensitive, but not resistant cells (Figure 3.8 a and b). In 
addition, p21, a downstream target of p53, was robustly induced by both Flu and 
IR in sensitive cells, whereas FluR cells showed only a delayed induction in 
response to IR (Figure 3.8 c), suggesting an attenuated p53 function in FluR 
cells.  
Importantly, any perturbation of p53 pathway — either activation or 
inhibition — has been reported to induce autophagy. p53 is known to activate 
BECN1-dependent autophagy through JNK-mediated phosphorylation of 
BCL2.(179) Besides, cytoplasmic p53 is well established to inhibit autophagy 
(180). In our preliminary experiments, pifithrin-α, a transcriptional inhibitor of 
p53(181), did not affect Flu-mediated autophagy in Nalm-6 cells although p21 
upregulation was inhibited (Figure 3.8 d). However, regulation of autophagy by 
p53 would require more detailed investigations that are beyond the scope of this 
study. Nevertheless, from our data it is conceivable that in FluR cells p53 
inactivation may be associated with both inhibition of cytotoxic (BECN1-
dependent) and activation of cytoprotective autophagy (AMPK/ULK-1-
dependent). Therefore, inhibition of autophagy could possibly be a treatment 
strategy for CLL patients with defective p53. 
 
96 
 
Figure 3.8 Fludarabine-resistance is associated with p53 inactivation . Western 
blot analysis for the levels of p53 and p21 in (a) Nalm-6 versus their derivative 
FluR and (b) Reh versus their derivative FluR cells in response to fludarabine 
(Flu)-treatment for the indicated time. (c) Western blot analysis for the levels of 
p53 and p21 in Nalm-6 versus their derivative FluR in response to 5 Gy ionizing 
radiation (IR)-treatment for the indicated time. (d)Western blot for LC-3 I/II, p21 in 
Nalm-6 cells pretreated with 10 Μm Pifithrin-α (PFT- α) for 1 h followed by 4 h 
treatment with Flu. β-actin was used as a loading control   
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In conclusion, our data establish that autophagy can have a differential 
outcome on cell death or cell survival.In Flu-sensitive cells, a BECN1-dependent 
signaling mechanism mediates autophagic cell death in response to Flu, whereas 
FluR cells become addicted to basal autophagy that is required for their cell 
survival. This transition is achieved by simultaneous increase in the MCL-
1/BECN1 interaction to inhibit cell death-associated BECN1-dependent 
autophagy, as well as activation of BECN1-independent and AMPK-dependent 
autophagy. In addition to autophagy, BIM-dependent apoptosis is critical for cell 
death due to Flu and FluR cells escape this cell death pathway by regulating BIM 
levels. These data suggest that elevated basal autophagy or low BIM levels, 
such as that seen in FluR cells may be useful to predict patient response to 
chemotherapy and/ or autophagy inhibition. These findings have important 
implication in designing novel therapeutic regimens for CLL patients. Although 
induction of autophagy may be a useful strategy to induce cell death in Flu-
sensitive patients, these findings suggest that paradoxically, inhibition of 
autophagy may be a viable treatment strategy for CLL patients that have 
demonstrated Flu resistance.   
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CHAPTER IV 
Targeting mTORC1-mediated metabolic addiction to overcome 
FluDARABINE resistance in malignant  
B cells  
 
4.1 Introduction 
Fludarabine (Flu; also known as F-ara-A) is a purine analog that is 
indicated in the treatment of hematological malignancies, including chronic 
lymphocytic leukemia (CLL) (124) and indolent non-Hodgkin lymphomas (182). 
Although Flu-based regimens have been successful in improving the outcome in 
patients, primary or acquired resistance limits the effectiveness of this therapy 
(124). 
Recent research in B-cell malignancies, including CLL and non-Hodgkin 
lymphomas, suggests that constitutive activation of B-cell receptor-associated 
cellular signaling pathways and cues from the microenvironment are the key 
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regulators for survival and maintenance of these cancers, as well as their 
response to chemotherapy (130). A critical downstream component of the B-cell 
receptor signaling pathway is the mammalian target of rapamycin (mTOR) kinase 
that is regulated by the phosphatidylinositol 3-kinase (PI3K)/acutely transforming 
retrovirus (Akt) pathway (131, 132). The mTOR kinase occurs in two distinct 
complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (7). 
Akt activates mTORC1, which in turn phophorylates p70S6 kinase (p70S6K) and 
the eukaryotic-initiation-factor 4E-binding protein-1 (4EBP1), whereas mTORC2 
phosphorylates and activates Akt (7, 132). 
Aberrant activation of mTORC1 occurs in the most common human 
cancers, suggesting that mTORC1 signaling confers survival and proliferative 
advantages to cancer cells (25). Therefore, allosteric inhibitors of mTORC1, 
rapamycin and its analogs (rapalogs) represent an attractive therapy for various 
tumors, including hematological malignancies (183, 184). However, these drugs 
failed to induce significant apoptosis of either cycling or quiescent cells and 
showed modest clinical responses that were also associated with toxicity (184). 
The mechanism of resistance to rapalogs is attributed to their ability to inhibit 
only one of several downstream targets of PI3K, leaving Akt unaffected. 
Moreover, they also disrupt a feedback mechanism that dampens PI3K activity, 
leading to a compensatory upregulation of Akt activity, causing counterproductive 
prosurvival effects. On the contrary, the ATP-competitive dual PI3K/mTORC1/2 
and mTORC1/2 inhibitors display potent anticancer properties both in vitro and in 
vivo in a wide range of malignancies, including leukemia (184, 185). Several of 
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these compounds are being tested in preclinical models and they show a 
consistently robust effect against tumors driven by PI3K/Akt signaling, while they 
are ineffective against tumors driven by mutations of Ras, which can signal 
through multiple pathways, such as those for  MEK and ERK (186)..  
An alternative approach for inhibiting mTORC1 is to target its downstream 
effectors. A previous study, using unbiased genomic and metabolomic 
approaches, reported that gene sets related to specific metabolic pathways, 
including the pentose phosphate pathway, fatty acid biosynthesis, glycolysis, and 
cholesterol biosynthesis, comprised the top 20 mTORC1-induced genes (18). 
mTORC1 stimulates protein synthesis by regulating mRNA translation and 
ribosome biogenesis (20). Additional recent reports suggest regulation of 
glutamine (187) and pyrimidine metabolism by mTORC1 (17, 19, 188). 
Consistently, targeting the enzymes comprising metabolic pathways has been 
recently evaluated in various mTORC1-dependent cancer settings (189, 190).  
As mTORC1 is associated with poor treatment outcomes in B-cell 
malignancies (191), we examined the significance of mTORC1 pathway 
activation in Flu-resistant (FluR) cells that were generated by chronic exposure to 
Flu. Moreover, we investigated the metabolic consequences of mTORC1 
activation in FluR cells, aiming to identify their selective vulnerability to 
interference with specific metabolic pathways. Our study reveals mTORC1-
dependent increase in glycolysis and mitochondrial respiration in FluR cells. In 
addition, there was an increase in de novo pyrimidine biosynthesis, which in turn 
led to addiction to mitochondrial respiration in FluR cells. We propose targeting 
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de novo pyrimidine biosynthesis and mitochondrial respiration as potential 
strategies to overcome Flu resistance. 
 
4.2 Results 
4.2.1 Fludarabine  resistance is associated with hyper mTORC1 activation 
 Deregulated mTORC1 activity is frequently associated with a variety of 
human cancers (25), including leukemia (12, 191) and negatively influences the 
response to chemotherapy (191). To determine how mTORC1 regulates Flu-
resistance, we derived Flu-resistant (FluR) cells from initially sensitive Nalm-6 
and Reh cells (148). Examination of phospho-p70S6K (T389) using 
immunoblotting as an assay of mTORC1 activation status revealed higher 
mTORC1 activation in FluR -Nalm-6, -Reh, and CLL derived Mec-2 cell  
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Figure 4.1 Fludarabine resistance is associated with mTORC1 activation. (a,b) 
Protein expression analysis of p-p70S6K, as a marker of mTORC1 activation in 
the indicated cell lines by immunoblot. β-actin was used as a loading control. 
IC50, as determined in (c), is indicated at the bottom. (c) Dose response for the 
effect of 24 h Fludarabine (Flu) treatment on cell growth in the indicated cell 
lines, as determined by the MTS assay. Data are expressed as mean ± SD 
(n=3). (d) Protein expression analysis of p-p70S6K and p70S6K in the indicated 
primary CLL cells. Numbers indicate CLL patient numbers. FluR, Flu resistant; 
FluS, Flu sensitive (e) Effect of 48 h Flu treatment on apoptosis in the indicated 
primary CLL cells, as determined by annexin V/PI staining and flow cytometry. % 
cell death following Flu treatment was normalized to % cell death in control cells 
using the formula:  (Livecontrol- LiveFlu/ Livecontrol)*100.   
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lines compared to parental Flu-sensitive (FluS) Nalm-6 and Reh cells (Figure 
4.1A). We extended our findings to a panel of malignant B lineage cell lines by 
comparing Flu-sensitivity (Figure 4.1C), determined by dose-ependent effect of 
Flu on MTS reduction, and mTORC1 activation (Figure 4.1B) and found a 
remarkably strong correspondence between hyperphosphorylation of p70S6K 
and Flu-resistance. In addition, we identified a similar relationship between p-
p70S6K (Figure 4.1D) and Flu resistance (Figure 4.1E) in primary CLL cells. 
Thus, Flu resistance is associated with hyper-mTORC1 activation in B cell 
leukemia and lymphoma cell lines. 
4.2.2 mTORC1 activation is critical for survival of FluR cells 
 Next, we studied the effect of mTORC1 inhibition on cell death using two 
different rapalogs, rapamycin (Rap) and everolimus (Ev), alone or in combination 
with Flu, in FluS versus FluR cells. In Nalm-6, a FluS cell line, 100 nM Rap alone 
did not induce apoptosis and, in fact, may have led to reduced cleaved-caspase-
3 in the presence of Flu (Figure 4.2A). In contrast, in Nalm-6-FluR cells, 
mTORC1 inhibition alone did induce cleaved-caspase-3 (Figure 4.2A). However, 
Rap (Figure 4.2A) did not sensitize FluR cells to Flu. Rap (100 nM) inhibited 
mTORC1 as measured by decreased phosphorylation of p70S6K in FluR cells 
(Figure 4.2B). Annexin V/PI staining further confirmed that Rap induced 
apoptosis in Nalm-6-FluR, but not in parental FluS Nalm-6 cells (Figure 4.2C). 
Similar data were obtained with Ev in Nalm-6 and Nalm-6-FluR cells (Figure 
4.2D).  
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 Figure 4.2. mTORC1 inhibition  causes moderate cell death in FluR cells 
and does not enhance the cytotoxic efficacy of Flu. (a) Western blot analysis for 
cleaved caspase-3 and β-actin, as a loading control, in Nalm-6 and Nalm-6-Flu-
resistant (Nalm-6-FluR) cells following inhibition of mTORC1 using Rap in 
combination with Flu. (b) Nalm-6-FluR cells were treated with the indicated 
concentrations of rapamycin (Rap) and cell lysates analyzed by western blotting 
for p-p70S6K and p70S6K. (c) Nalm-6 and Nalm-6-FluR cells were treated with 
the indicated concentrations of Rap for 48 h and cell death was determined using 
annexin V/ PI staining. (d) Nalm-6 and FluR cells were treated with everolimus 
(Ev) and analyzed by western blotting for the levels of indicated proteins. β-actin 
was used as a loading control. Primary CLL cells were treated with (e) Flu ± Rap 
or Rap alone and (f) Flu ± Ev or Ev alone for 48 h and cell death was determined 
by annexin V/ PI staining. Data represent mean ± SD (n=7), *p<0.05.  
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 Importantly, we found similar results in primary CLL cells cultured ex vivo, 
indicating that Rap (Figure 4.2E) or Ev (Figure 4.2F) alone induces significant 
cell death (p<0.05), but does not enhance sensitivity to Flu, as measured by 
annexin V/PI-staining. These findings suggest that even though constitutive  
mTORC1 activation is critical for survival of FluR cells, mTORC1 inhibition does 
not overcome Flu resistance. 
4.2.3 High basal mTORC1 activation leads to higher aerobic glycolysis and 
oxygen consumption rates in FluR cells 
The efficacy of mTORC1 inhibition is limited by compensatory activation of 
oncogenic pathways due to loss of negative feedback on the upstream PI3K/Akt 
pathway and by regulation of mTORC1 by other signaling pathways (1, 184, 
186). Therefore, we intended to investigate whether targeting downstream 
functions of mTORC1 activation was an effective alternative to overcome Flu 
resistance. As recent studies suggest that activation of oncogenic pathways, 
including mTORC1, must induce metabolic reprogramming in order to provide 
ATP and substrates for biosynthesis to support tumor growth (3), we next 
investigated whether FluR cells had different metabolic requirements than FluS 
cells.  
We measured two metabolic parameters: the extracellular acidification rate 
(ECAR) and oxygen consumption rate (OCR) using a label-free system with the 
Seahorse XF-24 Metabolic Flux Analyzer. ECAR correlates with the rate of 
glycolysis because lactic acid is produced from pyruvate generated through 
glycolysis, in order to replenish the NAD+ needed for glycolysis. OCR represents 
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mainly the mitochondrial respiration rate. We found that Nalm-6-FluR cells had a 
significantly higher basal rates of glycolysis (p<0.001; Figure 4.3A) and 
mitochondrial respiration (p<0.0001; Figure 4.3B) compared with Nalm-6 cells. 
Ev treatment significantly inhibited both ECAR (p<0.02) (Figure 4.3A) and OCR 
(p<0.001) (Figure 4.3B) in FluR cells, suggesting that mTORC1 regulates both 
glycolysis as well as mitochondrial respiration in FluR cells.  
As 2-deoxyglucose (2-DG) is an inhibitor of hexokinase, the first enzyme 
required for glycolysis, it also inhibits glycolysis and thus, glucose utilization. 
Addition of 2-DG blocked ECAR in both untreated as well as Ev-treated Nalm-6-
FluR cells (Figure 4.3A), confirming that ECAR was a specific measure of 
glycolysis. Moreover, Ev treatment for 16 h had no effect, whereas bendamustine 
(Bd), which is known to induce apoptosis in FluR cells (148), led to cytochrome c 
release in FluR cells (Figure 4.3C), indicating that the decrease in OCR following 
Ev treatment was not an outcome of mitochondrial membrane permeabilization 
(156).  
We next defined the metabolic profile of Nalm-6 and Nalm-6-FluR cells using 
a series of mitochondrial chemical probes (192). Oligomycin blocks ATP 
synthesis (and degradation) by the F0 /F1 ATPase, therefore, reducing the OCR in 
cells in which oxygen consumption is coupled to ATP synthesis. A decrease in 
basal OCR on addition of oligomycin thus provides an estimation of mitochondrial 
ATP synthesis. Trifluorocarbonylcyanide phenylhydrazone (FCCP) disrupts the 
proton gradient across the inner mitochondrial membrane and therefore 
uncouples the electron transport chain from oxidative phosphorylation. As a 
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result, the electrons continue to pass through the chain and reduce oxygen to 
water, but with no ATP synthesis taking place. As a consequence, mitochondrial 
oxygen consumption abruptly increases when FCCP is added to coupled cells. 
Moreover, the response to the  
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Figure 4. 3. Constitutive mTORC1 activation leads to metabolic re-programming 
in FluR cells. Untreated Nalm-6 parental (95,000 cells/well), untreated or 16 h 
Ev-treated Nalm-6-FluR (50,000 cells/well) cells were seeded in V7 Seahorse 
tissue culture plates. (a) The basal extracellular acidification rate (ECAR) was 
calculated for each well for 45 min. In the case of Nalm-6-FluR-untreated and 
everolimus (Ev)-treated cells, ECAR was subsequently measured for another 45 
min following 100 mM 2-deoxyglucose (2-DG) injection as a control to validate 
ECAR as a specific measure of glycolysis. (b) A series of basal oxygen-
consumption rates (OCR) were measured for untreated or Ev treated Nalm-6 
parental and derivative Nalm-6-FluR cells for the first 45 min and then following 
sequential injection of 1.5 μM oligomycin, 1.5 μM trifluorocarbonyl-
cyanidephenylhydrazone (FCCP), and 0.75 μM rotenone + antimycin A. (c) 
Nalm-6 FluR cells were treated as indicated for 16 h. Mitochondria-free cytosol 
was then prepared and cytochrome c release was analyzed by western blotting. 
(d) Nalm-6 and Nalm-6-FluR cells were plated at 10,000 cells /well in 96-well 
plates and treated as indicated for 2 h and ATP was assayed using the 
mitochondrial ToxGlo assay from Promega. Data are presented as counts per 
second (cps) of luminescence intensity per 10,000 cells. Nalm-6, Nalm-6-FluR, 
and Mec-2 cells were: (e) treated with 200 mM 2-DG or cultured in glucose-free 
media for 72 h, or (f) treated with 0.75 μM rotenone and antimycin A for the 
indicated times and cell death was determined by annexin V/PI staining. Data 
represent mean ± SD (n=3), *p<0.05,**p<0.01,  ***p<0.001, ****p<0.0001. 
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combination of rotenone and antimycin A, which blocks the respiratory chain at 
complexes 1 and 3, respectively, provides a measure of non-mitochondrial 
oxygen consumption. The nearly complete inhibition of OCR with rotenone and 
antimycin A confirmed that OCR is, indeed, a measure of mitochondrial oxygen 
consumption (Figure 4.3B). Oligomycin treatment reduced the OCR, which then 
abruptly rose when FCCP was added (Figure 4.3B). These data indicate that 
mitochondrial function is not compromised in either Nalm-6 or Nalm-6-FluR cells.  
Nevertheless, there was only a low decrease in basal OCR on addition of 
oligomycin (<70%) (Figure 4.3B), whereas the maximal OCR achieved using 
optimal concentrations of FCCP was close to the basal OCR in both cell lines 
(Figure 4.3B). These results suggest that the higher basal OCR in FluR cells was 
not coupled to higher ATP synthesis. 
 Consistently, we found no significant difference in the basal ATP levels 
between Nalm-6 and Nalm-6-FluR cells (Figure 4.3D). 2-DG inhibition of 
glycolysis significantly decreased ATP levels in Nalm-6 as well as Nalm-6-FluR 
cells (p<0.001) (Figure 4.3D), however, the fold decrease in ATP due to 2-DG 
treatment, as compared to respective controls, was almost twice as much in the 
resistant cells as it was observed in the FluS cells. These results suggest that 
glycolysis contributes to ATP synthesis in both cell types. however, FluR cells 
depend more than FluS cells on glycolysis. Moreover, both cell types showed a 
much greater decrease in ATP levels with inhibition of glycolysis than with 
inhibition of the electron transport chain using rotenone and antimycin A (Figure 
4.3D), further confirming that oxidative phosphorylation is inefficiently coupled to 
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ATP synthesis in these cell lines. Thus, mTORC1 activation led to higher rates of 
glycolysis and mitochondrial respiration in FluR cells. Moreover, higher OCR was 
not related to higher ATP synthesis in FluR cells. 
Consistently, even though 2-DG induced apoptosis in FluS as well as FluR 
cells, the Nalm-6-FluR (p<0.05) and Mec-2 FluR (p<0.01) cells were significantly 
more sensitive to 2-DG than the FluS Nalm-6 cells (Figure 4.3E). Glucose 
deprivation, however, had no effect on survival of Nalm-6-FluR and Mec-2 FluR 
cells, but was significantly more toxic to the FluS Nalm-6 cells, p<0.001 (Figure 
4.3E). The opposite effects on cell death due to 2-DG and glucose deprivation in 
FluS and FluR cells suggest that FluS, but not FluR cells, depended more on 
exogenously added glucose for glycolysis.  
Interestingly, treatment with antimycin A and rotenone to inhibit mitochondrial 
respiration induced significant cell death in a time-dependent manner in Nalm-6-
FluR [48 h (p<0.01), 72 h (p<0.0001)] and Mec-2 [(48 h (p<0.001), 72 h 
(p<0.0001)] cells (Figure 4.3F). In contrast, cell death was negligible in Nalm-6 
cells up to 72 h (Figure 4.3F).  
Overall, these results indicate that mTORC1 activation leads to higher rates 
of glycolysis and mitochondrial respiration in FluR cells, which translated into 
higher sensitivity of FluR cells to pharmacological inhibition of glycolysis as well 
as mitochondrial respiration. However, the effect of inhibition of mitochondrial 
respiration was much more profound in FluR cells, whereas FluS cell survival 
depended on glycolysis, and not mitochondrial respiration. Thus, these data 
indicate that mitochondrial respiration is a potential target to overcome Flu 
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resistance.                                                                                                                                  
4.2.4 FluR cells have higher de novo pyrimidine synthesis  
Given our findings that inhibition of mitochondrial respiration was selectively 
toxic to FluR compared to FluS cells, and that the higher OCR was not coupled 
to higher ATP synthesis in FluR cells, we next investigated potential downstream 
effects. The mitochondrial respiratory chain has been shown to be involved in de 
novo pyrimidine biosynthesis via the activity of the enzyme dihydroorotate 
dehydrogenase (DHODH).(193) mTORC1 promotes glutamine flux through 
pyrimidine synthesis via p70S6K, which directly phosphorylates CAD (carbamoyl-
phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase) on 
Ser-1859, leading to its oligomerization and increased activity (17, 19).  
We found higher levels of phosphorylated Ser1859-CAD in FluR than in FluS 
cell lines (Figure 4.4A), which corresponded to greater phosphorylated p70S6K 
levels (Figure 4.4A). Inhibiting mTORC1 with Ev diminished phosphorylation of 
both CAD and p70S6K (Figure 4.4B). Therefore, higher activation of CAD in FluR 
cells was indeed an outcome of higher mTORC1 activation. Moreover, PALA [N-
(phosphonacetyl)-L-aspartate], a pharmacological inhibitor of CAD (194) 
synergized with Flu to induce cell death in FluR cells (Figure 4.4C). And, 
inhibition of de novo pyrimidine biosynthesis using PALA and leflunomide, 
inhibitor of DHODH, decreased the clonogenic 
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Figure. 4.4 Constitutive mTORC1 activation activates CAD in FluR cells. (a) 
Western blot analysis of Ser1859-CAD and p-P70S6K protein expression in the 
indicated cell lines. (b) Nalm-6 and Nalm-6-FluR cells were treated with 
everolimus (Ev) for 24 h, and cell lysates were analyzed by western blotting for p-
p70S6K (T389) and pCAD (S1859). (c) Combination Index- Fraction affected plot 
of the effect of combination of Fludarabine (Flu) and N-(phosphonacetyl)-l-
aspartate (PALA) on clonogenic cell survival in Nalm-6-FluR cells. (d) Effect of 
PALA and leflunomide treatment on clonogenic cell survival in Nalm-6-FluR cells. 
(e) Cell death analysis in siControl and si-p70S6K-expressing Nalm-6-FluR cells 
in response to 24 h Flu treatment as determined by annexin V/ PI staining. (f) 
Cell cycle distribution in the indicated cell lines was determined by BrdU and 7-
AAD double staining and FACS analysis. Data represent mean ± SD (n = 3 
independent experiments), **p<0.01. 
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survival of FluR cells (Figure 4.4D). To unambiguously define the role of 
mTORC1 activation on CAD signaling through p70S6K, we next modulated 
p70S6K expression levels. Remarkably p70S6K knockdown by siRNA in FluR 
cells caused massive cell death (Figure 4.4E), Increased de novo synthesis of 
pyrimidines, as a result of CAD activation, favors progression through S phase of 
the cell cycle because of the increased DNA synthesis (195). Consistently, we 
found a significantly higher S-phase population in Nalm-6-FluR (p<0.05), Mec-1, 
and Mec-2 cells compared to Nalm-6 cells (Figure 4.4F).  
Thus, high mTORC1 activation leads to CAD phosphorylation, which 
provides a survival advantage to FluR cells. These findings indicate that 
mTORC1 activation in FluR cells leads to their selective dependence on 
mitochondrial respiration for pyrimidine biosynthesis (Figure 4.5). Importantly, we 
show that this specific metabolic dependence of FluR cells can be effectively 
exploited by pharmacological inhibition of mitochondrial respiration to induce cell 
death in FluR cells.  
4.3 Discussion 
In this study we establish that mTORC1 activation, as measured by p-p70S6K 
T389, defines malignant B-cell response to Flu. This study reveals that mTORC1 
activation in FluR cells is associated with specific metabolic adaptation, which 
renders these cells highly vulnerable to the inhibition of mitochondrial respiration 
and de novo pyrimidine biosynthesis. Aberrant activation of mTORC1 signaling is 
a common feature of human cancers, 
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Figure. 4.5 Model for targeting metabolic vulnerability of FluR cells. 1. 
Hyperactive mTORC1 is associated with Flu-resistance. 2. mTORC1 causes 
higher rates of glycolysis, as measured by extracellular acidification rate (ECAR) 
and mitochondrial respiration, as measured by oxygen consumption rate (OCR), 
both of which are essential for FluR cell survival. Inhibition of mitochondrial 
respiration using rotenone and antimycin induces a more dramatic cell death 
than inhibition of glycolysis using 2-deoxyglucose, However, the increase in OCR 
is not related to ATP synthesis.  3. Infact, constitutive mTORC1 activation causes 
CAD S1859 phosphorylation in FluR cells, which leads to de novo pyrimidine 
biosynthesis and promotes survival in these cells. As such, FluR cells are also 
highly susceptible to inhibition of de novo pyrimidine biosynthesis using PALA 
and leflunomide, 4. Dihydroorotate dehydrogenase (DHODH), an essential 
enzyme in de novo pyrimidine biosynthesis, requires mitochondrial respiratory 
chain electron acceptors to oxidize dihydroorotate (DHO) to orotate, Thus, high 
mitochondrial respiration contributes to increase in de novo pyrimidine 
biosynthesis, in addition to other functions in FluR cells.  
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including hematological malignancies (132, 196). In addition, inhibition of B-cell 
receptor-associated signaling pathways, including mTORC1, is a potential 
treatment target in B cell malignancies, including CLL (12). p-p70S6K T389 
activation status per se has not been previously studied in the context of CLL or 
Flu-responsiveness. We show that mTORC1 activation correlates with Flu 
resistance in a panel of leukemic cell lines and in primary CLL cells. Despite high 
mTORC1 activity in FluR cells, mTORC1 inhibition by rapalogs had limited effect 
on cell death, likely due to the previously identified feedback activation of other 
oncogenic pathways (27). 
To address these limitations, we evaluated an alternative approach by targeting 
downstream metabolic reprogramming associated with mTORC1 activation in 
FluR cells (18). Consistent with the well-established role of mTORC1 in 
regulation of cellular metabolism, our study highlights three important aspects of 
metabolic reprogramming in FluR compared to parental Nalm-6 cells. FluR cells 
exhibited: (i) accelerated rates of glycolysis and mitochondrial respiration, (ii) 
higher de novo pyrimidine biosynthesis, as suggested by hyper-phosphorylation 
of CAD, and (iii) cell death in response to inhibition of mitochondrial respiration 
and de novo pyrimidine biosynthesis. 
An increased rate of glycolysis in the presence of sustained OCR has been 
previously reported in leukemic cells, using electrons from non-glucose carbon 
sources (197). Glutamine-dependent, glucose-independent Krebs cycle activity 
has been also reported in glioblastoma and melanoma cells (197).  
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Our data suggest that both FluS and FluR cells utilize glycolysis for ATP 
synthesis, therefore, cell death occurs in both cases in response to 2-DG. 
However, FluR cells are sensitive to a greater extent to 2-DG, which indicates 
that FluR cells are more dependent on glycolysis for ATP synthesis and overall 
survival, which, in turn, can be explained by an overall increase in biosynthetic 
pathways, such as pyrimidine biosynthesis. Nevertheless, the higher cell death in 
Nalm-6 cells than FluR cells in response to glucose starvation seems 
contradictory. However, it suggests that the resistant cells have adapted to 
survive without exogenous glucose. Thus, Flu-sensitive cells require exogeneous 
glucose, and hence they die in response to glucose starvation. In contrast, FluR 
cells make their own glucose by activation of endogeneous glucose-deprivation 
response pathways, such as autophagy (198) which, therefore, do not die in 
response to lack of glucose in the cell culture media.  
High glycolysis and intracellular utilization of glucose coexisting with lower 
dependence on exogenous glucose due to Increased expression of the glucose 
deprivation response network, including unfolded protein response, autophagy, 
glucagon signaling, and gluconeogenesis, genes, has been described before in 
the context of acquired resistance to lapatinib in breast cancer cell lines (137). 
Selective targeting of these pathways associated with glucose-deprivation could 
overcome resistance (137). Similarly, we recently reported that FluR cells could 
be selectively targeted by inhibition of autophagy (148). Thus, glucose 
deprivation response pathways could potentially be targeted to overcome Flu 
resistance.  
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Treatment with mitochondrial toxins induced robust cell death in FluR cells. 
Although we observed higher OCR in FluR than in parental Nalm-6 cells, with 
carefully titrated concentrations of FCCP both cell lines demonstrated basal OCR 
close to their maximal capacities. Yet, coupling efficiency was low in both cell 
lines. Moreover, the two cell lines showed no significant difference in ATP levels. 
Overall, these results suggest that the higher OCR in FluR cells was not coupled 
to higher ATP synthesis.  
Mitochondrial respiration in hematopoietic and various other cell types is known 
to be affected by de novo pyrimidine synthesis in a Krebs cycle- and glucose-
independent manner (197). Moreover, mTORC1 activation was recently shown to 
enhance glutamine flux through pyrimidine biosynthesis (17, 124) and 
leflunomide was reported to overcome Flu resistance in CLL (199). Consistent 
with those data, we found higher pCAD (S1859) levels in FluR cells. Moreover, 
inhibition of pyrimidine biosynthesis using two different inhibitors, PALA and 
leflunomide, reduced clonogenic survival of FluR cells. Importantly, PALA acted 
synergistically with Flu in inducing cell death in FluR cells. These findings 
conclusively establish that constitutive mTORC1 activation promotes de novo 
pyrimidine synthesis in FluR cells, to which they are addicted.  
Notably, p70S6K knockdown induced remarkable cell death in FluR cells 
compared to FluS cells. This further supports the importance of 
mTORC1/p70S6K/CAD axis in regulating pyrimidine biosynthesis and, therefore, 
survival in FluR cells. The fact that rapalog treatment, despite reducing active 
p70S6K levels more effectively than S6K knockdown, was less effective in 
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inducing cell death, seems intriguing. However, rapalog treatment will also affect 
other targets of mTORC1 which, in turn, may be associated with pro-survival 
pathways (1). For example, mTORC1 inhibition activates the ULK-1 (ATG1) 
complex which, in turn, will activate autophagy, which is indeed a well 
established pro-survival pathway (200). Consistently, we have previously 
reported that FluR cells depend on autophagy for their survival (148). Therefore, 
these findings further underscore the importance of targeting downstream 
pathways in mTORC1-dependent cancers. 
We recognize that OxPhos inhibition may cause cell death due to multiple 
reasons, e.g. inhibition of recycling of NAD+ (201), inhibition of de novo 
pyrimidine biosynthesis (202), ROS(203) and, disruption of MMP leading to 
Bax/Bak oligomerisation (197). Nevertheless, our data suggest that one of the 
reasons should be de novo pyrimidine biosynthesis given high proportion of S-
phase cells and high pCAD S1859. The DHODH enzyme, a critical component of 
this pathway, is located in the inner mitochondrial membrane and must use 
mitochondrial electron transfer chain (ETC) components, i.e. ubiqinone as the 
proximal acceptor and coenzyme q as the ultimate electron acceptor, in order to 
carry out oxidation of DHO to orotate. 
In summary, we established mTORC1 activation, as measured by p-p70S6K 
T389, and downstream pCAD S1859 as potential biomarkers of Flu-resistance in 
leukemic cells (Figure 4.5). FluR cells depend on mTORC1-dependent de novo 
pyrimidine biosynthesis and mitochondrial respiration for survival. Thus, directly 
targeting de novo pyrimidine biosynthesis pathway enzymes using PALA and 
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leflunomide, or targeting mitochondrial respiration represent effective strategies 
to overcome Flu resistance.   
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CHAPTER V 
SUMMARY AND CONCLUSIONS 
5.1 Summary of major findings 
The present work has focused on investigating mTORC1 pathway as a 
potential target in FluR cells. Given the limited effectiveness of rapalogs due to 
activation of prosurvival pathways, we investigated whether targeting 
downstream functions of mTORC1 was more effective than rapalogs in inducing 
cell death in mTORC1-dependent cancer cells,  
Since oncogenic activation Is associated with metabolic reprogramming to 
promote tumor growth, we explored activation and the possibility of targeting 
downstream metabolic consequences of mTORC1 activation in FluR cells. 
Secondly, autophagy, an important consequence of mTORC1, plays an 
important role in chemoresistance. However, autophagy can increase or 
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decrease cell death in response to chemotherapy, We investigated the role of 
autophagy in regulating cell death and resistance in the context of Flu. 
Key research findings include (Figure 5.1): 
1. In Flu-sensitive cells, Flu-induced cell death associated BECN1-
dependent autophagy. 
2. MCL-1 degradation following Flu treatment released BIM and BECN1, 
leading to apoptosis and cell death-associated autophagy in Flu-sensitive 
cells. In FluR cells there was low BIM expression and BECN1 was 
inhibited by high MCL-1/BECN1 interaction. 
3. p-p70S6K (T389), a marker of mTORC1 activation, predicted Flu 
response in a panel of cell lines and primary CLL cells, however, 
mTORC1 inhibition produced meager cell death and did not enhance the 
efficacy of Flu. 
4. mTORC1 causes higher rates of glycolysis, as measured by ECAR and 
mitochondrial respiration, as measured by OCR, both of which are 
essential for FluR cell survival.  
5. Inhibition of mitochondrial respiration using rotenone and antimycin 
induces a more dramatic cell death than inhibition of glycolysis using 2-
deoxyglucose, However, the increase in OCR is not related to ATP 
synthesis.  
6. Constitutive mTORC1 activation causes CAD S1859 phosphorylation in 
FluR cells, which leads to de novo pyrimidine biosynthesis and promotes 
survival in these cells. As such, FluR cells are also highly susceptible to 
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inhibition of de novo pyrimidine biosynthesis using PALA and leflunomide, 
Thus, high mitochondrial respiration contributes to increase in de novo 
pyrimidine biosynthesis, in addition to other functions in FluR cells.  
7. FluR cells have a higher metabolic demand, which activates AMPK-
dependent, and BECN1-independent autophagy and promotes survival in 
these cells. 
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Figure 5.1 A schematic diagram illustrating that both mTORC1 and BECN1-
independent autophagy are critical determinants of survival in FluR cells. (a) 
MCL-1 degradation following Flu treatment freed the pro-apoptotic (b) BIM and 
(c) the key mediator of autophagy, BECN1, leading to cell death-associated 
autophagy in Flu-sensitive cells(148). (d) Low BIM expression and (e) BECN1 
sequestration by sustained MCL-1 prevented cell death in FluR cells. (f) 
mTORC1 activation in FluR cells causes (1) increased levels and dependence on 
glycolysis and (2) mitochondrial respiration, and (3) CAD phosphorylation that 
leads to de novo pyrimidine biosynthesis. (g) This metabolic adaptation provides 
survival advantage to FluR cells. (h) mTORC1–dependent metabolic 
reprogramming also renders FluR cells addicted to AMPK-dependent, BECN1-
independent  autophagy ( Sharma, Janocha et al. in revision, 148).  
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5.2 Conclusions 
To conclude, our studies address clinically relevant question in mTOC1 
biology. We show that targeting downstream consequence of mTORC1 
activation, de novo pyrimidine biosynthesis and oxidative phosphorylation in FluR 
cells is indeed an effective mechanism to overcome resistance, compared to 
targeting mTORC1 itself (Figure. 5.1).  
Further, our findings contribute towards addressing a long standing 
question of context-dependent, prodeath versus prosurvival, function of 
autophagy (Figure. 5.1). Flu treatment induces BECN1-dependent autophagic 
cell death in FluS cells, whereas FluR cells that are under metabolic stress are 
dependent on basal AMPK-dependent BECN1-independent autophagy. We 
propose, upstream stimuli (overstimulation by chemotherapy treatment versus 
stimulation by metabolic stress within cellular threshold limits), and molecular 
regulatory inputs (BECN1-dependent versus AMPK-dependent) could be 
determining factors for prodeath versus prosurvival function of autophagy.  
In the future studies, the molecular mechanisms connecting the various 
pathways that have been identified in this work, as contributing to Flu-resistance 
should be addressed.  
Some of the important questions, include— What is the mechanism of 
mTORC1 activation in FluR cells? How autophagy and mTORC1 both can be 
active in FluR cells? Whether basal autophagy in FluR cells contributes to the 
rapalog resistance observed? What is the exact contribution of autophagy in 
terms of surviving metabolic stress in FluR cells?   What is the mechanism of 
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BECN1-independent autophagy?  What is the mechanism by which mTORC1 
upregulates glucose metabolism? What advantage this selective metabolic 
adaptation (high OCR, ECAR, high pyrimidine biosynthesis) offers to FluR cells? 
What other pathways mTORC1 targets? Last, but not the least understanding 
magnitude and nature of upstream stimuli; identification of specific molecular 
mechanisms associated with different outcomes of autophagy observed in FluR 
versus Flu-sensitive cells are warranted.  
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CHAPTER VI 
FUTURE DIRECTIONS 
UNCOUPLING OF mTORC1 ACTIVATION AND AMPK-DEPENDENT 
AUTOPHAGY IN FLUDARABINE RESISTANT LEUKEMIC CELLS  
 
6.1 Mechanism of mTORC1 activation in FluR cells 
  We show using various markers, including p-p70S6K T389, p-PS6K 
235/236, and pmTOR 2481 (Figure 6.1 a and Chapter IV) that Flu- resistance is 
associated with hyperactivation of mTORC1 pathway, mTORC1 regulates cell 
growth in response to five major signals – growth factors, energy status, oxygen,  
and amino acids (discussed in chapter1).  
The TSC complex is the central node that delivers regulatory inputs from 
various upstream pathways (discussed in chapter 1). We did not find any 
significant differences in TSC complex components between Nalm-6 FluS and -
FluR cells (Figure.6.1b). 
Growth factor pathway dependent regulation.  The levels of pAkt S473, a 
marker of PI3K pathway, and Erk1/2 T202/Y204, a marker of MAPK pathway 
activation, were higher in FluR than FluS cells (Figure 6.1b), suggesting the 
134 
 
growth factor signaling pathway activation upstream of mTORC1 activation.  
Further CAL 101 (a PI3K delta isoform inhibitor), diminishes constitutive Akt and 
mTORC1 activation in Mec-2 cells (Figure 6.1c).  
Growth factor pathway activation (discussed in chapter 1) may be further 
investigated in the future, including the TSC complex (phosphorylation status of 
particularly Akt/PKB-target sites, i.e. S939, Y1571, and T1462, and Erk target 
sites, including S540 and S664. Akt is also known to increase mTORC1 
activation by promoting PRAS40 dissociation from the mTORC1 complex. 
Therefore, mTORC1 complex formation may be investigated.  
Energy stress.  Energy stress activates AMPK, which inhibits mTORC1 
either by direct phosphorylation of mTORC1 or activation of TSC, an upstream 
inhibitor of mTORC1 pathway, leading to induction of autophagy (discussed in 
chapter 1). We observed co-existence of AMPK and mTORC1 activation in FluR 
cells (Chapter III, and Figure 6.1b), which is contradictory to the well established 
role of AMPK to inhibit mTORC1.  Such uncoupling between mTORC1 and 
AMPK has never been reported before, and will be, therefore,  interesting to 
investigate further.  
Amino acids.  Interestingly, amino acids provide an essential signal that 
positively regulates mTORC1. The activation of mTORC1 by amino acids is 
known to be independent of TSC1/2, because the mTORC1 pathway remains 
sensitive to amino acid deprivation in cells that lack TSC1 or TSC2 (Nobukuni et 
al., 2005). In addition, the RAG GTPases recruit mTORC1 to lysosomes, where 
RHEB activates it (204). p62 is known to directly associate with active RAGs 
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Figure. 6.1 FluR cells have constitutive activation of mTORC1 which is critical for 
their survival. Nalm-6 and Nalm-6-FluR cells were treated with everolimus (Ev) 
for 24 h and (a) protein expression analysis of various markers of mTORC1 
activation was performed. (b) protein expression analysis of various upstream 
regulators of mTORC1 activation was performed.  (c) Mec-2 cells were treated 
with the indicated concentrations of CAL-101 for 24 h. and lysates were analyzed 
for the indicated proteins.  
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and mTORC1 via Raptor (205). Our preliminary data indicate that: (i) p62 levels 
and its co-localization with mTORC1 are higher in FluR than parental Nalm-6 
cells (Figure 6.2a and b), and (ii) ectopic expression of p62 is protective against 
Flu in Nalm-6 cells (Figure 6.2c and d), suggesting that p62/RAG GTPases/Rheb 
may be implicated in mTORC1 activation. 
Given that mTORC1 is regulated by various upstream pathways, however, 
the presence of amino acids has been shown to be essential for activation of the 
mTORC1 kinase. Our hypothesis is that energy stress-dependent regulation of 
autophagy in FluR cells occurs independent of mTORC1 inhibition. Therefore, 
FlR cells are inherently under glucose deprivation stress, but not amino acid 
starved. In support of this possibility, our preliminary data suggest that while 
mTORC1 inhibition is cytotoxic to FluR and not FluS cells (chapter IV), glucose 
deprivation induces cell death in FluS and not FluR cells (chapter IV). We 
propose that FluR cells have adapted themselves to survive metabolic stress by 
constitutive activation of glucose deprivation response pathways, such as 
autophagy. Therefore, they do not depend on exogenous glucose supply, as 
reported recently for imatinib-resistant breast cancer cell lines (137).  
The mTORC1 and autophagy pathways in response to pharmacological 
inhibition of AMPK, and glucose starvation may be investigated, which will 
provide important insight into the regulation of mTORC1 and autophagy by 
AMPK.  The TSC complex (levels of TSC complex components, phosphorylation  
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Figure 6.2 The p62-mTORC1 connection (a) Levels of p62, as determined by 
immunoblotting, in Nalm-6, Nalm-6-FluR, Reh, Reh-FluR cells. β-actin was used 
as loading control. (b, c) Immunofluorescence staining showing colocalization of 
mTOR/p62 in Nalm-6 and Nalm-6-FluR cells. (d, e) Nalm-6 cells were transfected 
with GFP-Control or WT p62, and cell death was determined following 24 h Flu 
treatment. 
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Status of particularly AMPK target sites, i.e. T1227 and S1345, and Raptor 
phosphorylation at S792 may be investigated.  
An important question is how is mTORC1 able to maintain a critical 
balance of metabolic demand with supply, in the absence of AMPK regulatory 
check on it. The cross-talk between mTORC1 and AMPK may be further 
investigated. In yeast, mTORC1 has been shown to inhibit Snf1 (AMPK 
homologue), however, nothing is known in higher eukaryotes. Our hypothesis is 
that in order to maintain energy homeostasis, mTORC1, infact, activates AMPK,  
which then induces ULK-1 activation and autophagy in FluR cells. Investigation 
of AMPK and autophagy pathway in response to pharmacological inhibition of 
mTORC1, and amino acid starvation will provide important insight into the 
regulation of mTORC1 and autophagy by AMPK. 
 
6.2 Mechanism of co-activation of mTORC1  and autophagy  in FluR cells 
The co-dependence of FluR cells on mTORC1 activation and constitutive 
autophagy is surprising as mTORC1 is known to inhibit autophagy by direct 
phosphorylation of ULK-1 at S757 (Chapter 1). mTORC1 can spatially segregate 
from the autophagy initiation complex by formation of specialized membrane 
compartments, designated TOR-Autophagy Spatial Coupling Compartments 
(TASCCs, Figure 6.3 a).(206) In that case, active mTORC1 is located at the 
lysosome, as shown by co-localization of mTORC1 and LAMP2, with ULK-1 
being excluded from TASCC.  
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FluR cells have, indeed, a much higher co-localization of LAMP2 with 
mTORC1 than with ULK-1 (Figure 6.3 b, c), suggesting that spatial uncoupling 
between ULK-1 and mTORC1 due to TASCC formation may enable the ULK-1 
complex to, at least partially, escape inhibition by mTORC1.  
However, Ev was still able to induce autophagy and enhance autophagic 
flux, as shown by LC3 II accumulation (Figure 6.3d) and p62 degradadation 
which could be rescued by CQ (Figure 6.3d) in FluR cells. These data suggests 
that autophagy, at least in part, was still regulated by mTORC1. However, the 
level of autophagy induction in response to mTORC1 inhibition was considerably 
reduced in FluR cells compred to Nalm-6 (Figure 6.3 d).  
Thus, we propose that the autophagy inhibitory function of mTORC1 is 
diminished in FluR cells, but may not be completely lost, due to partial spatial 
uncoupling between mTORC1 and ULK-1. Consistent with the absence of 
TASCCs in Nalm-6 cells (Figure 6.3 b, c), Ev induced higher LC3 II processing. 
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Figure 6.3 The autophagy inhibitory function of mTORC1 is diminished in FluR 
cells due to TASCC. (a) TOR-autophagy spatial coupling compartment (TASCC) 
, a unique cytoplasmic compartment, which is highly enriched for both mTOR and 
the end stage and autophagic vesicles (exclusively autolysosomes). 
Autophagosomes form at the cell periphery and as they mature, fuse with 
lysosomes that contain mTORC1, giving rise to the TASCC. (b,c) 
Immunofluorescence staining showing colocalization of ULK1/LAMP2 and 
mTOR/LAMP2 in Nalm-6 and Nalm-6-FluR cells. (d) Nalm-6 and Nalm-6-FluR 
cells were pretreated with everolimus (Ev) for 24 h followed by 24 h CQ 
treatment and lysates were analyzed for the indicated proteins. 
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(Figure 6.3d) and p62 (Figure 6.3 d) degradation than in FluR cells. Overall our 
data suggest that, there is an alternative mechanism of autophagy regulation, in 
addition to mTORC1, in FluR cells. Under energy deficit conditions, AMPK is 
known to activate ULK1 by either direct phosphorylation, i.e. AMPK-ULK1 or by 
inhibiting mTORC1,  i.e. AMPK-mTORC1-ULK1. 
  In our previous studies we have shown higher pULK1 S467, an AMPK 
target site, in FluR cells. In addition, we showed that pULK1 S467 could be 
inhibited using compound c, an AMPK inhibitor (148). In future studies, the levels 
of mTORC1- and AMPK-dependent regulatory phosphorylation sites on ULK-1, 
and the AMPK/ULK-1 interaction should be further investigated to fully 
understand ULK-1 kinase activation (207). Downstream of ULK-1, mTORC1 
directly phosphorylates and inhibits ATG14-containing VPS34 complexes.  
Our data suggest that the BECN1-complex is inhibited by BCL-2 family 
proteins in FluR cells (148). Whether inhibition of mTORC1 activates ATG14-
containing the VPS34 complex may be investigated. Further investigation of this 
phenomena—mechanism and role of mTORC1-independent regulation of 
constitutive autophagy in FluR cells will enhance our understanding of the 
process of autophagy. We believe there must be a rationale behind existence of 
two different paths from AMPK to ULK1. The two must differ in upstream inputs 
and/ or in downstream consequences, which need to be evaluated more carefully 
to fully appreciate the functions and regulation of autophagy. 
 
6.3 BECN1-indepdendent autophagy in FluR cells 
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Because basal autophagy was still observed in Fl-R cells despite BECN1 
inhibition by MCL-1, it is likely that autophagy in Fl-R cells is independent of 
BECN1. BECN1-independent autophagy has been reported in cardiac myocytes, 
where protective autophagy was stimulated in an AMPK-dependent manner in 
response to glucose deprivation or ischemia (173). Non-canonical, BECN1-
independent autophagy, dependent on ATG7 and ATG12/ATG5 has been 
reported in various settings, including development and proliferation of late-stage 
peripheral lymphocytes (208) and in response to apoptotic stimuli such as 
staurosporine, resveratrol, or H2O2 (41). There are clear reports in the literature 
showing autophagic cell death through BECN1  in canonical autophagy pathways 
(119, 173). An important question is how can membrane nucleation happen 
independently of BECN1?  
Recently, a BECN1 homolog, BECN2, has been identified that associates 
with VPS34 kinase and other members of the BECN1 complex, including VPS34, 
BCL-2, and AMBRA1. BECN2 participates in autophagy independent of BCL-2 
dissociation in response to starvation (209). In order to study whether basal or 
inducible autophagy in FluR cells depends on BECN2, we investigated levels as 
well as interactions of BECN2 with MCL-1 and BCL-2. Our data suggest that the 
levels of BECN2 protein are the same in control and Flu-treated Nalm-6 and 
Nalm-6-FluR cells (Figure 6.4a). Further, our immunoprecipitation studies 
suggest that in FluR cells, BECN2 associates strongly with BCL-2 in untreated, 
and BECN2/BCL-2 interaction does not change following Ev treatment (Figure 
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6.4b). Thus, consistent with He et al. studies (209), BCL-2 doesnot seem to 
regulate the function of BECN2. 
 In contrast, while we did not find any interaction between BECN2 and 
MCL-1 in untreated FluR cells (Figure 6.4b), The BECN2/MCL-1 interaction was 
observed following Ev treatment (Figure 6.4b). This suggests that constitutive, 
prosurvival autophagy may require BECN2. However, following Ev treatment 
which, in turn induces cell death in FluR cells (Chapter IV), MCL-1 dependent 
inhibition of BECN2 blocks this prosurvival pathway. Thus, it will be interesting to 
study further whether this switch between BECN1 and BECN2 binding to MCL-1 
may be an important determinant of prodeath versus prosurvival autophagy. 
 How BECN2 and BECN1 interact with MCL-1 under various prodeath 
stimuli in FluR cells, such as Ev and obatoclax can be investigated. Whether 
BECN1 or 2 is in complex with Atg14L, UVRAG in Flu-sensitive versus FluR cells 
may be studied to fully understand regulation of BECN-activity and the role of 
BECN1/2-dependent autophagy in regulating Flu-resistance. In addition, ULK1 
directly activates the VPS34 complex by phosphorylating AMBRA1 (210). Given 
that AMBRA1 binds much tighter to BECN2 than to BECN1, it is possible that the 
basal autophagy in FluR cells depends on AMBRA1 phosphorylation of the 
BECN2-containing pool of VPS34 complex. The 
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Figure 6.4 Constitutive prosurvival autophagy in FluR cells is mediated by 
BECN2. (a) Nalm-6 FluR cells were treated with Flu for 24 h and cell lysates 
were analyzed for the indicated proteins. (b)  Nalm-6 FluR cells were treated with 
Ev for 24 h, and MCL-1 and BCL-2 immunoprecipitates were analyzed for the 
presence of the indicated proteins. 
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effect of AMBRA1 kinase-dead mutant on autophagy in FluR cells may be 
investigated.  
Furthermore, although BECN1 plays a central role in autophagy in the 
recruitment of other autophagy proteins to the pre-autophagosomal membrane 
(121), are autophagy-independent functions of BECN1 1 can not be ruled out. 
For example, heterozygous disruption of BECN1 in mice results in increased 
spontaneous tumorigenesis (121). Further investigation is therefore needed to 
clarify the role of BECN1- inhibition in mediating cell survival or cell death in 
response to Fl. 
Our studies suggest an intricate connection between mTORC1, metabolic 
reprogramming, and autophagy pathways in FluR cells. Understanding the 
precise regulatory mechanisms in the two-way flow of information among these 
pathways will profoundly enhance understanding of drug resistance mechanisms, 
and holds promise in the identification of novel therapeutic targets. 
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‘’We come just after dawn. When resources are scarce, we attack the 
weakest of us, the deformed and outcast. We invaginate us, drenching 
our bodies with acid until we are unrecognizable. Then we eat us. We 
are hungry. We are literally starving. This is not only how we survive; 
it’s how we purge evil and stay pure.’’ 
 -David Delp 
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